

**International Journal of Epidemiology**ije.oxfordjournals.orgInt. J. Epidemiol. (2012) 41 (1): 79-105. doi: 10.1093/ije/dyr154
First published online: December 13, 2011**Environmental chemical exposures and human epigenetics**Lifang Hou^{1,2,*}, Xiao Zhang¹, Dong Wang^{1,3} and Andrea Baccarelli⁴[+](#) Author Affiliations[✉](#) *Corresponding author. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1400, Chicago, IL 60611, USA. E-mail: l-hou@northwestern.edu

Accepted September 15, 2011.

Abstract

Every year more than 13 million deaths worldwide are due to environmental pollutants, and approximately 24% of diseases are caused by environmental exposures that might be averted through preventive measures. Rapidly growing evidence has linked environmental pollutants with epigenetic variations, including changes in DNA methylation, histone modifications and microRNAs.

Environmental chemicals and epigenetic changes All of these mechanisms are likely to play important roles in disease aetiology, and their modifications due to environmental pollutants might provide further understanding of disease aetiology, as well as biomarkers reflecting exposures to environmental pollutants and/or predicting the risk of future disease. We summarize the findings on epigenetic alterations related to environmental chemical exposures, and propose mechanisms of action by means of which the exposures may cause such epigenetic changes. We discuss opportunities, challenges and future directions for future epidemiology research in environmental epigenomics. Future investigations are needed to solve methodological and practical challenges, including uncertainties about stability over time of epigenomic changes induced by the environment, tissue specificity of epigenetic alterations, validation of laboratory methods, and adaptation of bioinformatic and biostatistical methods to high-throughput epigenomics. In addition, there are numerous reports of epigenetic modifications arising following exposure to environmental toxicants, but most have not been directly linked to disease endpoints. To complete our discussion, we also briefly summarize the diseases that have been linked to environmental chemicals-related epigenetic changes.

Key words [Environmental chemicals](#) [epigenetics](#) [disease susceptibility](#)

Background

More than 13 million deaths every year are due to environmental pollutants, and as much as 24% of diseases are estimated to be caused by environmental exposures that can be averted.¹ In a screening promoted by the United States Center for Disease Control and Prevention, 148 different environmental chemicals were found in the blood and urine from the US population, indicating the extent of our exposure to environmental chemicals.² Growing evidence suggests that environmental pollutants may cause diseases via epigenetic mechanism-regulated gene expression changes.^{3,4} Dynamic chromatin remodelling is required for the initial steps in gene transcription, which can be achieved by altering the accessibility of gene promoters and regulatory regions.⁵ Epigenetic

factors, including DNA methylation, histone modifications and microRNAs (miRNAs) (Figure 1), participate in these regulatory processes, thus controlling gene expressions.^{6,7} Changes in these epigenetic factors have been shown to be induced by exposure to various environmental pollutants, and some of them were linked with different diseases.⁸⁻¹⁰ In this review, we summarize the findings linking environmental chemical exposures with epigenetic alterations, provide some evidence linking such epigenetic changes with diseases (Table 1), and discuss the challenges and opportunities of environmental epigenomics in epidemiologic studies.




Figure 1
Transcriptional regulation at the epigenetic level.

Epigenetic mechanisms, including DNA methylation, histone modifications and miRNAs, regulate chromatin compaction and gene expression. DNA methylation at CpG sites usually suppresses gene

expression. Histones are globular proteins that undergo posttranslational modifications, such as Ac, methylation and phosphorylation, thus influencing chromatin structure and gene expression. Active genes are usually characterized by low DNA methylation and highly acetylated chromatin configuration that allow access to transcription factors. miRNAs are a set of small, non-protein-coding RNAs that negatively regulate expression of target genes at the posttranscriptional level by binding to 3'-untranslated regions of target mRNAs

View this table:
In this window In a new window

Table 1
Effects of environmental chemicals on epigenetic

changes

Epigenetic factors

DNA methylation

DNA methylation, a naturally occurring modification that involves the addition of a methyl group to the 5' position of the cytosine ring, is the most commonly studied and best understood epigenetic mechanism.¹¹ In the human genome, it predominantly occurs at cytosine-guanine dinucleotide (CpG) sites, and serves to regulate gene expression and maintain genome stability.¹²

Environmental studies have shown distinct DNA methylation abnormalities. One commonly reported alteration is an overall genome-wide reduction in DNA methylation content (global hypomethylation) that may lead to reactivation of transposable elements and alter the transcription of otherwise silenced adjacent genes.^{13,14} Global hypomethylation is associated with genomic instability and an increased number of mutational events.¹⁵⁻¹⁸ There are approximately 1.4 million Alu repetitive elements (sequences containing a recognition site for the restriction enzyme *Afl*)¹⁹ and a half a million long interspersed nucleotide (LINE-1) elements in the human genome that are normally heavily methylated.²⁰ More than one-third of DNA methylation occurs in repetitive elements.²⁰ Because of their high representation throughout the genome, LINE-1 and Alu have been used as global surrogate markers for estimating the genomic DNA methylation level in cancer tissues,²⁰⁻²² although recent data show lack of correlation with global methylation in normal tissues, such as peripheral blood.²³ Other types of abnormalities that can be induced by environmental pollutants are hyper- or hypo-methylation of specific genes or regions, potentially associated with aberrant gene transcription.²⁴⁻²⁷ DNA methylation alterations that directly affect gene expression often

occur in the CpG sites located in the promoter regions of the genes. Recent evidence has shown that differentially methylated sites in various cancer tissues are enriched in sequences, termed 'CpG island shores', up to 2 kb distant from the transcription start site.²⁸ However, to date, gene-specific DNA methylation alterations induced by environmental exposures have been mostly investigated in gene promoter regions. CpG island shores are clearly worthy of further investigation in relation to environmental exposures, but whether they hold such importance in a non-cancer setting remains to be determined.

Histone modifications

In humans, protection and packaging of the genetic material are largely performed by histone proteins, which also offer a mechanism for regulating DNA transcription, replication and repair.²⁹ Histones are nuclear globular proteins that can be covalently modified by acetylation (Ac), methylation, phosphorylation, glycosylation, sumoylation, ubiquitination and adenosine diphosphate (ADP) ribosylation,^{30,31} thus influencing chromatin structure and gene expression.^{32,33} The most common histone modifications that have been shown to be modified by environmental chemicals are Ac and methylation of lysine residues in the amino terminal of histone 3 (H3) and H4. Histone Ac, with only a single acetyl group added to each amino acid residue usually, increases gene transcriptional activity;³⁴⁻³⁷ whereas histone methylation (Me), found as mono (Me), di-methyl (Me₂), and tri-methyl (Me₃) group states³⁸ can inhibit or increase gene expression depending on the amino acid position that is modified.³⁹⁻⁴¹

miRNAs

miRNAs are short single-stranded RNAs of approximately 20–24 nucleotides in length that are transcribed from DNA but not translated into proteins. miRNAs negatively regulate expression of target genes at the post-transcriptional level by binding to 3'-untranslated regions of target mRNAs.⁴² Each mature miRNA is partially complementary to multiple target mRNAs and directs the RNA-induced silencing complex (RISC) to identify the target mRNAs for inactivation.⁴³ miRNAs are initially transcribed as longer primary transcripts (pri-miRNAs) and processed first by the RNase enzyme complex, and then by Dicer, leading to incorporation of a single strand into the RISC. miRNAs guide RISC to interact with mRNAs and determine post-transcriptional repression. miRNAs are involved in the regulation of gene expression through the targeting of mRNAs during cell proliferation, apoptosis, control of stem cell self renewal, differentiation, metabolism, development and tumour metastasis.^{44,45} Compared with other mechanisms involved in gene expression, miRNAs act directly before protein synthesis and may be more directly involved in fine-tuning of gene expression or quantitative regulation.^{46,47} Moreover, miRNAs also play key roles in modifying chromatin structure and participating in the maintenance of genome stability.⁴⁸ miRNAs can regulate various physiological and pathological processes, such as cell growth, differentiation, proliferation, apoptosis and metabolism.^{42,49} More than 10 000 miRNAs have been reported in animals, plants and viruses by using computational and experimental methods in miRNA-related public databases. The aberrant expression of miRNAs has been linked to various human diseases, including Alzheimer's disease, cardiac hypertrophy, altered heart repolarization, lymphomas, leukaemias, and cancer at several sites.⁵⁰⁻⁶⁶

Environmental pollutants and epigenetic alterations

Metals

Heavy metals are widespread environmental contaminants and have been associated with a number of diseases, such as cancer, cardiovascular diseases, neurological disorders and autoimmune diseases.^{67,68} In recent years, there has been an increasing appreciation of the roles of molecular factors in the aetiology of heavy metal-associated diseases.⁶⁹⁻⁷¹ Several studies showed that metals act as catalysts in the oxidative deterioration of biological macromolecules.⁷² Metal ions induce reactive oxygen species (ROS), and thus lead to the generation of free radicals.^{72,73} ROS

accumulation can affect epigenetic factors.⁷⁴⁻⁷⁹ Growing data have linked epigenetic alterations with heavy metal exposure.

Arsenic

Evidence has been rapidly increasing that exposure to arsenic (As) alters DNA methylation both globally and in the promoter regions of certain genes. Upon entering the human body, inorganic As is methylated for detoxification. This detoxification process uses S-adenosyl methionine (SAM), which is a universal methyl donor for methyltransferases including DNA methyltransferases (DNMTs) that determine DNA methylation. Thus, it has been shown that As exposure leads to SAM insufficiency and decreases the activity of DNMTs due to the reduction of their substrate. In addition, As has also been shown to decrease *DNMT* gene expression.⁸⁰ These As-induced processes may all contribute to global DNA hypomethylation. Arsenic exposure was shown to induce global hypomethylation in a dose-dependent manner in several *in vitro* studies.⁸⁰⁻⁸³ Further, rats and mice exposed to As for several weeks exhibited global hypomethylation in hepatic DNA.⁸⁴⁻⁸⁷ Nonetheless, evidence in humans is still limited and not completely consistent. In a cross-sectional study of 64 subjects, As level in contaminated water was associated with global DNA hypermethylation in blood mononuclear cells.⁸⁸ A global dose-dependent hypermethylation of blood DNA was observed in Bangladeshi adults with chronic As exposure.⁸⁹

Arsenic exposure has also been associated with gene-specific hyper- or hypo-methylation in both experimental settings and human studies.^{85,90-101} As exposure has been shown to induce dose-dependent promoter hypermethylation of several tumour suppressor genes, such as *p15*, *p16*, *p53* and *DAPK*, *in vitro* and *in vivo*.^{91,93,98,101,102} Furthermore, As exposure-related up-regulation of *ER-alpha*, *c-myc* and *Ha-ras1* gene expression was linked to their promoter hypomethylation in cell lines^{94,95} and animal studies.^{84,85,97} Evidence in humans is rapidly growing. Toenail As concentration was positively associated with *RASSF1A* and *PRSS3* promoter methylation levels in bladder tumours.¹⁰⁰ Promoter hypermethylation in these two genes was associated with As-induced invasive lung tumours compared with non-invasive tumours.¹⁰⁰ Promoter hypermethylation of *DAPK* was observed in human uroepithelial cells exposed to As,⁹⁰ as well as in tumours from 13 of 17 patients living in As-contaminated areas relative to 8 of 21 patients living in As non-contaminated areas.⁹⁹ Increased DNA methylation of the *p16* promoter was observed in arseniasis patients when compared with people with no history of As exposure.¹⁰¹

Arsenic exposure has also been shown to cause alterations in histone modifications. The earliest evidence on As-induced histone acetylation reductions was in *Drosophila*.¹⁰³ Trivalent As has recently been linked to reduced H3 and H4 lysine 16 (H4K16) acetylation in human bladder epithelial cells.¹⁰⁴ On the other hand, trivalent As exposure has also been shown to increase histone acetylation, which was shown to up-regulate genes related to apoptosis or cell stress response.^{105,106} Ramirez *et al.* have reported that As could cause global histone acetylation by inhibiting the activity of histone deacetylases (HDACs).¹⁰⁷ Together, these studies provide evidence that histone acetylation can be dysregulated by As exposure. Early in 1983, As was also shown to induce methylation changes in H3 and H4 in *Drosophila*.¹⁰³ Similar results on H3 were seen in *Drosophila* Kc 111 cell several years later.^{108,109} In recent years, in mammalian cells, arsenite (AsIII) exposure has been associated with increased H3 lysine 9 dimethylation (H3K9me2) and H3 lysine 4 trimethylation (H3K4me3), and decreased H3 lysine 27 trimethylation (H3K27me3).^{110,111} As was shown to induce apoptosis by up-regulation of phosphorylated H2AX¹¹² and cause H3 phosphorylation, which may play important roles in the up-regulation of the oncogenes.¹⁰⁶

Exposure of human lymphoblast cell line TK-6 to arsenite exhibited global increases in miRNA expression.¹¹³ Arsenic trioxide (As₂O₃) has been used as a pharmacological treatment in acute promyelocytic leukaemia.¹¹⁴ Cao *et al.*¹¹⁵ demonstrated that numerous miRNAs were up-regulated or down-regulated in T24 human bladder carcinoma cells exposed to As₂O₃.

In particular, miRNA-19a was substantially decreased, resulting in cell growth arrest and apoptosis. The As-related changes in miRNA expression were shown to be reversible when the exposure was removed.¹¹⁵

Nickel

Nickel has been proposed to increase chromatin condensation and trigger *de novo* DNA methylation of critical tumour suppressor or senescence genes.¹¹⁶ In Chinese hamster G12 cells transfected with the *Escherichia coli* guanine phosphoribosyl transferase (*gpt*) gene, nickel was shown to induce hypermethylation and inhibit the expression of the transfected *gpt* gene.¹¹⁷ An animal study has further shown that nickel induced DNA hypermethylation, altered heterochromatin states and caused gene inactivation, eventually leading to malignant transformation.¹¹⁸ Govindarajan *et al.*¹¹⁹ have observed DNA hypermethylation of *p16* in nickel-induced tumours of wild-type C57BL/6 mice, as well as in mice heterozygous for the tumour suppressor *p53* gene injected with nickel compound.

Nickel may cause diseases also via affecting histone modifications. Evidence on nickel-induced histone modifications includes increases of H3K9 dimethylation, loss of histone acetylation in H2A, H2B, H3 and H4, and increases of the ubiquitination in H2A and H2B.^{116,120-127} An increase in H3K9 dimethylation and a decrease in H3K4 methylation and histone acetylation was found in the promoter of the *gpt* transgene in G12 cells exposed to nickel.^{116,123,128} In mouse PW cells and human cells treated with the HDAC inhibitor trichostatin A, nickel showed a lower capacity to induce malignant transformation.¹²⁹ This finding suggested that gene silencing mediated by histone deacetylation may play a critical role in nickel-induced cell transformation.¹²⁹ In addition, nickel has also been shown to induce a loss of histone methylation *in vivo* and decreased activity of histone H3K9 demethylase *in vitro*.¹²³ Nickel also suppresses histone H4 acetylation *in vitro* in both yeast and mammalian cells.^{130,131} Nickel can induce H3 phosphorylation, specifically in serine 10 (H3S10) via activation of the c-jun N-terminal kinase/stress-activated protein kinase pathway.¹³²

Cadmium

Cadmium (Cd) has been shown to alter global DNA methylation.¹³³ Takiguchi *et al.*¹³⁴ demonstrated that Cd inhibits DNMTs and initially induces global DNA hypomethylation *in vitro* (TRL1215 rat liver cells). However, prolonged exposure was shown to lead to DNA hypermethylation and enhanced DNMTs activity in the same experiment.¹³⁴ Cd can also decrease DNA methylation in proto-oncogenes and promote oncogenes expression that can result in cell proliferation.^{133,134}

Transcriptional and post-transcriptional gene regulation is critical in responses to Cd exposure, in which miRNAs may play an important role.^{135,136} Bollati *et al.*¹³⁷ have recently demonstrated that increased expression of miR-146a in peripheral blood leucocytes from steel workers was related to inhalation of Cd-rich air particles. miRNA-146a expression is regulated by the transcription factor nuclear factor-kappa B, which represents an important causal link between inflammation and carcinogenesis.¹³⁸

Other metals

Mercury (Hg) is widely present in various environmental media and foods at levels that can adversely affect humans and animals. Exposure to Hg has been associated with brain tissue DNA hypomethylation in the polar bear.¹³⁹ Arai *et al.*¹⁴⁰ have studied the effects of Hg on DNA methylation status in mouse embryonic stem cells. After 48 or 96 h of exposure to the chemical, they observed hypermethylation of *Rnd2* gene in Hg-treated mouse embryonic stem cells.

Lead is among the most prevalent toxic environmental metals, and has substantial oxidative properties. Long-term exposure to lead was shown to alter epigenetic marks. In the Normative Aging Study, LINE-1 methylation levels were examined in association with patella and tibia lead levels, measured by K-X-Ray fluorescence. Patella lead levels were

associated with reduced LINE-1 DNA methylation. The association between lead exposure and LINE-1 DNA methylation may have implications for the mechanisms of action of lead on health outcomes, and also suggests that changes in DNA methylation may represent a biomarker of past lead exposure.¹⁴¹ In addition, Pilsner *et al.*¹⁴² characterized genomic DNA methylation in the lower brain stem region from 47 polar bears hunted in central East Greenland between 1999 and 2001. They have reported an inverse association between cumulative lead measures and genomic DNA methylation level.

Hexavalent chromium [Cr(VI)] is a mutagen and carcinogen that has been linked to lung cancer and other adverse health effects in occupational studies. Kondo *et al.*¹⁴³ found *p16* and *hMLH1* hypermethylation in lung cancer patients with past chromate exposure.¹⁴⁴ *In vitro* experiments on cells exposed to binary mixtures of benzo[a]pyrene (B[a]P) and chromium have shown that B[a]P activates Cyp1A1 transcriptional responses mediated by the aryl hydrocarbon receptor (AhR), whereas chromium represses B[a]P-inducible AhR-mediated gene expression^{145,146} by inducing cross-links of histone deacetylase 1-DNA methyltransferase 1 (HDAC1-DNMT1) complexes to the Cyp1A1 promoter chromatin and inhibit histone marks, including phosphorylation of histone H3 Ser-10, trimethylation of H3 Lys-4 and various acetylation marks in histones H3 and H4. HDAC1 and DNMT1 inhibitors or depletion of HDAC1 or DNMT1 with siRNAs blocked the chromium-induced transcriptional repression by decreasing the interaction of these proteins with the Cyp1A1 promoter and allowing histone acetylation to proceed. By inhibiting Cyp1A1 expression, chromium stimulate the formation of B[a]P DNA adducts. These findings may link histone modifications to chromium-associated developmental and carcinogenic outcomes.¹⁴⁷ Chromate exposure of human lung A549 cells has been shown to increase the global levels of di- and tri-methylated histone H3 lysine 9 (H3K9) and lysine 4 (H3K4), but decrease tri-methylated histone H3 lysine 27 (H3K27) and di-methylated histone H3 arginine 2 (H3R2). Most interestingly, H3K9 dimethylation was enriched in the human *MLH1* gene promoter following chromate exposure, and this was correlated with decreased *MLH1* mRNA expression. Chromate exposure increased the protein as well as mRNA levels of G9a, a histone methyltransferase that specifically methylates H3K9. This Cr(VI)-induced increase in G9a may account for the global elevation of H3K9 dimethylation. Furthermore, supplementation with ascorbate, the primary reductant of Cr(VI) and also an essential cofactor for the histone demethylase activity, partially reversed the H3K9 dimethylation induced by chromate. These results suggest that Cr(VI) may target histone methyltransferases and demethylases, which in turn affect both global and gene promoter-specific histone methylation, leading to the silencing of specific tumour suppressor genes.¹⁴⁸

Recent investigations have demonstrated that aluminum exposure can alter the expression of a number of miRNAs. miR-146a in human neural cells was up-regulated after treatment with aluminium sulphate. Up-regulation of miR-146a corresponded to the decreased expression of complement factor H, a repressor of inflammation.¹⁴⁹ In addition, a study on aluminium-sulphate-treated human neural cells in primary culture has shown increased expression of a set of miRNAs, including miR-9, miR-125b and miR-128.¹⁵⁰ The same miRNAs were also found to be up-regulated in brain cells of Alzheimer patients, suggesting that aluminum exposure may induce genotoxicity via miRNA-related regulatory elements.¹⁵⁰

Pesticides

Growing evidence suggests that epigenetic events can be induced by pesticide exposures.^{28,151-153} Animal models have shown that exposure to some pesticides, such as vinclozolin and methoxychlor, induces heritable alterations of DNA methylation in male germline associated with testis dysfunction,¹⁵⁴⁻¹⁵⁶ or affects ovarian function via altered methylation patterns.¹⁵⁷ Decreased methylation in the promoter regions of *c-jun* and *c-myc* and increased levels of their mRNAs and proteins were found in livers of mice exposed to dichloro- and trichloro-acetic acid.^{158,159} Dichlorvos has been demonstrated to induce DNA methylation in multiple

tissues in an animal toxicity study.¹⁶⁰ DNA methylation in repetitive elements in blood DNA was inversely associated with increased levels of plasma pesticide residues and other persistent organic pollutants in an Arctic population,¹⁶¹ a finding later confirmed in a similar study in a Korean population.¹⁶² Whether aberrant DNA methylation represents the link between pesticides and risks of pesticide-related disease, including the excess of cancer risk observed in some epidemiology studies,¹⁶³⁻¹⁶⁸ remains to be determined.

Dieldrin, a widely used organochlorine pesticide, has been shown to increase acetylation of core histones H3 and H4 in a time-dependent manner. Histone acetylation was induced within 10 min of dieldrin exposure, suggesting that histone hyperacetylation is an early event in dieldrin-induced diseases. Treatment with anacardic acid, a histone acetyltransferase inhibitor, decreased dieldrin-induced histone acetylation.¹⁶⁹ Dieldrin was further shown to induce histone hyperacetylation in the striatum and substantia nigra in mouse models, suggesting the roles for histone hyperacetylation in dieldrin-induced dopaminergic neuronal degeneration.¹⁷⁰

Air pollution

Exposure to particulate matter (PM) of ambient air pollution has been associated with increased morbidity and mortality related to cardiovascular and respiratory diseases.^{171,172} Black carbon, a component of PM derived from vehicular traffic, has been linked to decreased DNA methylation in LINE-1 repetitive elements in 1097 blood DNA samples of elderly men in the Boston area. Additional evidence for PM effects on DNA methylation stemmed from an investigation of workers in a steel plant with well-characterized exposure to PM with diameters of <10 µm (PM₁₀). Methylation of inducible nitric oxide synthase gene promoter region was decreased in blood samples of individuals exposed to PM₁₀ after 3 days of work in the foundry when compared with baseline.¹⁷³ In the same study, methylation of Alu and LINE-1 was negatively related to long-term exposure to PM₁₀.¹⁷³ In contrast, an animal experiment on mice exposed to air particles collected from a steel plant showed global DNA hypermethylation in sperm genomic DNA, a change that persisted after removal of environmental exposure.¹⁷⁴ Inhaled diesel exhaust particles' exposure and intranasal *Aspergillus fumigatus* induced hypermethylation of several sites of the *interferon gamma (IFNγ)* promoter and hypomethylation at a CpG site of the *IL-4* promoter in mice. Altered methylation of promoters of both genes was correlated with changes in IgE levels.^{175,176}

We recently also associated PM exposure with histone modifications in the above-mentioned steel workers with high exposure level to PM.¹⁷⁷ In this study, exposure duration (years of work in the foundry) was associated with increased H3K4me2 and H3K4ac in blood leucocytes.¹⁷⁷ In the same study, we showed that exposure to metal-rich PM induced rapid changes in the expression of two inflammation-related miRNAs, i.e. miR-21 and miR-222, measured in peripheral blood leucocytes.¹⁷⁸ Using microarray profiling, Jardim *et al.*¹⁷² have shown extensive alterations of miRNA expression profiles in human bronchial epithelial cells treated with diesel exhaust particles. Out of 313 detected miRNAs, 197 were either up- or down-regulated by at least 1.5-fold.¹⁷²

Benzene

Benzene is an environmental chemical that has been associated with increased risk of haematological malignancies, particularly with acute myeloid leukaemia and acute nonlymphocytic leukaemia.¹⁷⁹⁻¹⁸⁴ Benzene ranks among the top 20 chemicals for production volume in USA.¹⁸⁵ Our results from a study of police officers and gas-station attendants have shown that low-dose exposure to airborne benzene is associated with alterations in DNA methylation in blood DNA of healthy subjects that resemble those found in haematological malignancies,^{165-168,186} including hypomethylation of LINE-1 and Alu repetitive elements, hypermethylation of *p15* tumour suppressor gene and hypomethylation of *MAGEA1* (melanoma-associated antigen 1 gene). Consistently, reductions of global DNA methylation has been recently shown in human

lymphoblastoid cells treated with benzene metabolites.¹⁸⁷ *In vitro* experiments have also shown that benzene exposure induces hypermethylation of poly (ADP-ribose) polymerases-1 (*PARP-1*), a gene involved in DNA repair.¹⁸⁸

Bisphenol A

Bisphenol A (BPA) is an endocrine disruptor with potential reproductive effects, as well as a weak carcinogen associated with increased cancer risk in adult life through fetal exposures.^{189,190} BPA is widely used as an industrial plasticizer in epoxy resins for food and beverage containers, baby bottles and dental composites.¹⁹¹ Dolinoy *et al.*¹⁹² reported that periconceptional exposure to BPA shifted the coat colour distribution of the viable yellow agouti (*A^Y*) mouse offspring toward yellow by decreasing CpG methylation in an intracisternal A particle (IAP) retrotransposon upstream of the Agouti gene.¹⁹³ In this animal model, the yellow-coat phenotype is associated with increased cancer rates, as well as with obesity and insulin resistance. In the same set of experiments, maternal dietary supplementation, with either methyl donors like folic acid or the phytoestrogen genistein, blunted the effect of BPA on IAP methylation and prevented the coat colour change caused by BPA exposure.¹⁹² In pregnant CD-1 mice treated with BPA, Bromer *et al.*¹⁹⁴ found decreased methylation and increased expression of the homeobox gene *Hoxa10*, which controls uterine organogenesis. In breast epithelial cells treated with low-dose BPA, gene expression profiling identified 170 genes with expression changes in response to BPA, of which expression of lysosomal-associated membrane protein 3 (*LAMP3*) was shown to be silenced due to DNA hypermethylation in its promoter.¹⁹⁵

In a recent study by Avissar-Whiting *et al.*,¹⁹⁶ an elevated expression of miR-146a was observed in BPA-treated placental cell lines and miR-146a expression was associated with slower cell proliferation and higher sensitivity to the bleomycin-induced DNA damage.

Dioxin

Dioxin is a compound that has been classified as a human carcinogen by the International Agency for Research on Cancer. As dioxin is only a weak mutagen, extensive research has been conducted to identify potential mechanisms contributing to carcinogenesis. One proposed pathway to carcinogenesis is related to the powerful dioxin-induced activation of microsomal enzymes, such as CYP1B1, that might activate other procarcinogen compounds to active carcinogen. The capability of dioxin to induce *CYP1B1* has been recently shown *in vitro* to depend on the methylation state of the *CYP1B1* promoter.¹⁹⁷ Also, dioxin was shown to reduce the DNA methylation level of *Igf2* in rat liver.¹⁹⁸ Recently, alterations in DNA methylation at multiple genomic regions were identified in splenocytes of mice treated with dioxin, a finding potentially related to dioxin immunotoxicity.¹⁹⁹ In a xenograft mouse model of hepatocellular carcinoma, Elyakim *et al.*²⁰⁰ have also found that dioxin up-regulated miR-191. In the same study, inhibition of miR-191 inhibited apoptosis and decreased cell proliferation, suggesting that increased miR-191 expression may contribute to determine dioxin-induced carcinogenicity.

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX, also known as hexogen or cyclonite)

Hexahydro-1,3,5-trinitro-1,3,5-triazine (commonly known as RDX, the British code name for Royal Demolition Explosive) is an explosive polynitramine and common ammunition constituent used in military and civil activities. Although most of this environmental pollutant is found in soils, RDX and its metabolites are also found in water sources.²⁰¹ Exposure to RDX and its metabolites could cause neurotoxicity, immunotoxicity and cancers.²⁰² Zhang *et al.*²⁰² have recently evaluated the effects of RDX on miRNA expression in mouse brain and liver. In this study, out of 113 miRNAs, 10 were up-regulated and 3 were down-regulated. Most of the miRNAs that showed altered expression, including let-7, miR-17-92, miR-10b, miR-15, miR-16, miR-26 and miR-181, were found to regulate toxicant-metabolizing enzymes, as well as genes related to carcinogenesis and neurotoxicity.²⁰²

Diethylstilbestrol

Diethylstilbestrol (DES) is a synthetic oestrogen that was used to prevent miscarriages in pregnant women between the 1940s and the 1960s.²⁰³ A moderate increase in breast cancer risk has been shown both in daughters of women who were treated with DES during pregnancy, as well as in their daughters.²⁰⁴ Hsu *et al.*²⁰⁵ have demonstrated that the expression of 82 miRNAs (9.1% of the 898 miRNAs evaluated) were altered in breast epithelial cells when exposed to DES. In particular, the suppression of miR-9-3 expression was accompanied by promoter hypermethylation of the miR-9-3 coding gene in DES-treated epithelial cells.²⁰⁵

Chemicals in drinking water

Chlorination by-products are formed as a result of the water chlorination for anti-fouling purposes. Various chlorination by-products in drinking water, such as triethyltin,²⁰⁶ chloroform²⁰⁷ and trihalomethanes,²⁰⁸ have been questioned for potential adverse health effects.²⁰⁹ These chemicals have been shown to induce certain epigenetic changes. Rats that were chronically intoxicated with triethyltin in drinking water showed development of cerebral oedema as well as an increase of phosphatidylethanolamine-*N*-methyltransferase activities. This increased methylation might be a compensatory mechanism for counteracting the membrane damages induced by triethyltin.²⁰⁶ Chloroform, dichloroacetic acid (DCA) and trichloroacetic acid (TCA), three liver and kidney carcinogens, are by-products of chlorine disinfection found in drinking water.^{210,211} Mice treated with DCA, TCA and chloroform show global hypomethylation and increased expression of *c-myc*, a proto-oncogene involved in liver and kidney tumours.²⁰⁷ Trihalomethanes (chloroform, bromodichloromethane, chlorodibromomethane and bromoform) are regulated organic contaminants in chlorinated drinking water. In female B6C3F1 mouse liver, trihalomethanes demonstrated carcinogenic activity. Chloroform and bromodichloromethane decreased the level of 5-methylcytosine in hepatic DNA. Methylation in the promoter region of the *c-myc* gene was reduced by the trihalomethanes, consistent with their carcinogenic activity.²⁰⁸

Environmental epigenomics: challenges and opportunities for epidemiologic studies

The studies reviewed in this article have demonstrated the potential effects of environmental pollutants on the epigenome. Several of the epigenomic changes observed in response to environmental exposures might be mechanistically associated with susceptibility to diseases (Table 1). Further studies of epigenetic mechanisms in disease pathogenesis, including the role of epigenetics in the developmental origins of health and disease, their relationships with environmental exposures and the pathways associated with the disease phenotype may help develop preventive and therapeutic strategies.

Epigenetics and developmental origins of health and disease

During embryogenesis, epigenetic patterns change dynamically to adapt embryos to be fit for further differentiation.⁷ Two waves of epigenetic reprogramming, which take place at the zygote stage and during primordial germ cells formation, accompany mammalian development.²¹²

Experiments on mice carrying the *A^{Vy}* have demonstrated that embryo life is a window of exquisite sensitivity to the environment. In viable yellow (*A^{Vy}/a*) mice, transcription originating in a IAP retrotransposon inserted upstream of the *agouti* gene (*A*) causes ectopic expression of *agouti* protein, resulting in yellow fur, obesity, diabetes and increased susceptibility to tumours.²¹³ BPA is a high-production-volume chemical used in the manufacture of polycarbonate plastic. In utero or neonatal exposure to BPA is associated with higher body weight, increased breast and prostate cancer and altered reproductive function.

Additional experimental studies have suggested epigenetic mechanisms as potential intermediates for the effects of prenatal exposures to pesticides such as vinclozolin and methoxychlor,¹⁵⁴ as well as of other conditions such as nutritional supplies of methyl donors.¹⁹² Evidence has also been

accumulating in humans. Investigations of candidate loci among individuals prenatally exposed to poor nutrition during the Dutch famine in 1944–45 indicate that epigenetic changes induced by prenatal exposures may be common in humans, although they appear to be relatively small and greatly dependent on the timing of the exposure during gestation.^{214,215} Based on findings of changes in DNA methylation in subjects exposed to the Dutch famine, Heijmans *et al.*²¹⁶ have suggested that the epigenome may represent a molecular archive of the prenatal environment, via which the in-utero environment may produce serious ramifications on health and disease later in life. Terry *et al.*²¹⁷ found that prenatal exposure to cigarette smoke was associated with increased overall blood DNA methylation level in adulthood. Other examples include decreased LINE-1 and Sat 2 methylation level in adults and children prenatally exposed to smoking,²¹⁸ and global DNA hypomethylation in newborns with utero exposures of maternal smoking.²¹⁹ In addition to these DNA methylation changes, Maccani *et al.*²²⁰ have recently observed that miR-16, miR-21 and miR-146a were down-regulated in cigarette smoke-exposed placentas compared to controls.

Additional well-conducted epigenetic studies are now warranted to generate a catalogue of regions that are sensitive to the prenatal environment and may reflect developmental influences on human disease.

Can we develop epigenomic biosensors of past exposures?

An important property of epigenomic signatures is that, because they can be propagated through cell division even in cells with high turnover, they can persist even after the exposure is removed. In addition, as discussed above, an individual's epigenome may also reflect his/her prenatal environmental exposure experience. Thus, epigenomic profiling of individuals exposed to environmental pollutants might provide biosensors or molecular archives of one's past or even prenatal environmental exposures. Using epigenomics, exposure assessment might be brought to research investigations and preventive settings where repeated collections of exposure data might be unfeasible or exceedingly expensive. Further research is needed to establish how rapid are the changes induced by environmental pollutants, as well as whether they accumulate in response to repeated or continuous exposure and how long they persist after the exposure is removed.

What are suitable study designs and approaches for environmental epigenomics?

The field of environmental epigenetics has evolved rapidly in the past several years. As research applications grow, investigators will be facing several difficulties and challenges. Some studies have produced inconsistent results on same pollutants. Several factors may contribute to the inconsistencies. Epigenetic alterations are tissue specific.²²¹ It is conceivable that the same environmental pollutant may produce different epigenetic changes in different tissues, and even within the same tissue on different cell types. Larger studies with well-defined exposure information that allows examining epigenetic changes across different tissues are needed. Different study design, small sample size and different laboratory methods may also be major causes for the inconsistency. Replicating results and identifying the sources of variability across studies is a major challenge for epigenetic investigations. Because epigenetic markers change over time, disease outcomes are prone to reverse causation, i.e. an association between a disease and an epigenetic marker may be determined by an influence of the disease on the epigenetic patterns, rather than vice versa.²²² Although epigenetic alterations that were found to be induced by or associated with environmental pollutants were also found in various diseases, almost no study has examined the sequence of exposures, epigenetic alterations and diseases.

Longitudinal studies with prospective collection of objective measures of exposure, biospecimens for epigenetic analyses and preclinical and clinical disease outcomes are needed to appropriately establish causality. Existing prospective epidemiology investigations might provide resources for mapping epigenomic changes in response to specific chemicals. However,

cohort studies in which biospecimens have been previously collected for genetic or biochemical studies might pose several challenges. Most studies have collected biospecimens, such as blood, urine or buccal cells, which might not necessarily participate in the aetiology of the disease of interest. Methods of collection and processing (e.g. whole blood vs buffy coat) might modify the cell types stored, thus potentially impacting on epigenetic marks. In addition, high-coverage methods providing high-dimensional data on DNA methylation, histone modifications and miRNA expression are increasingly used in human investigations.

Albeit epigenetic mechanisms have properties that make them ideal molecular intermediates of environmental effects, the proportion of the effects of any individual environmental exposure that might be mediated through epigenetic mechanisms is still undetermined. Epidemiology and statistical approaches, including well-designed prospective studies and advanced statistical methods for causal inference are urgently needed. Similarly to genomic studies,²²³ epidemiological causal reasoning in epigenomics should include careful consideration of knowledge, data, methods and techniques from multiple disciplines.

The potential interactions between different forms of epigenetic modification

Most studies in environmental epigenetics have separately evaluated only one of the types of the epigenetic marks, i.e. DNA methylation, histone modifications or miRNA expression. However, epigenetic marks are related by an intricate series of interactions that may generate a self-reinforcing cycle of epigenetic events directed to control gene expression.²²⁴ For instance, histone deacetylation and methylation at specific amino acid residues contribute to the establishment of DNA methylation patterns. miRNA expression is controlled by DNA methylation in miRNA encoding genes, and, in turn, miRNAs have been shown to modify DNA methylation.²²⁵ Future studies that include comprehensive investigations of multiple epigenetic mechanisms might help elucidate the timing and participation of DNA methylation, histone modifications and miRNAs to determine environmental effects on disease development.

Can epigenomics be used for prevention?

One major objective of epidemiology investigations is to provide the groundwork for future preventive interventions. Numerous clinical and preclinical studies showed that most of the epigenetic changes are reversible, which offers novel insights to develop new preventive and therapeutic strategies that might take advantage of molecules that modify the activities of epigenetic enzymes, such as DNMTs and HDACs, as well as of the growing field of RNAi therapeutics. Drugs have been designed and developed that produce functional effects, such as histone acetylation and DNA hypomethylation that might be used to restore the normal transcription level of genes. Future epidemiology studies have a unique opportunity to evaluate whether the effects of environmental exposures on the epigenome are mitigated by positive changes in lifestyles, or worsened by the interaction with other risk factors. Future epigenomic research may provide information for developing preventive strategies, including exposure reduction, as well as pharmacological, dietary or lifestyle interventions.

Funding

Our work is partially supported by grants from the HSPH-NIEHS Center for Environmental Health New Investigator Fund (P30ES000002) and NIH award 1RC1ES018461-01.

Conflict of interest: None declared.

KEY MESSAGES

- Rapidly growing evidence has linked environmental pollutants with epigenetic variations, including changes in DNA methylation, histone modifications and microRNAs.
- Some of such epigenetic changes have been associated with various diseases.

- Further studies of epigenetic mechanisms in disease pathogenesis, their relationships with environmental exposures and related pathways are needed for the development of preventive and therapeutic strategies.
- Future epidemiology studies on environmental pollutants and epigenome face several challenges.

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2011; all rights reserved.

References

1. Prüss-Ustün Annette CC Organization (WHO): 2006 Preventing disease through healthy environments. Towards an estimate of the environmental burden of disease World Health. [Google Scholar](#)
2. Bollati V, Baccarelli A. Environmental epigenetics. *Heredity* 2010;105:105–12. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
3. Rezek S, Ulibaz F, Mach M, Navarova J, Dubovicky M. Developmental origin of chronic diseases: toxicological implication. *Interdiscip Toxicol* 2008;1:29–31. [CrossRef](#) [Medline](#) [Google Scholar](#)
4. Tang WY, Ho SM. Epigenetic reprogramming and imprinting in origins of disease. *Rev Endocr Metab Disord* 2007;8:173–82. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
5. Vaicicere T, Sawan C, Herrero Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. *Mutat Res* 2008;659:40–48. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
6. Crowl SI, Meazed D. Heterochromatin and epigenetic control of gene expression. *Science* 2003;301:798–802. [Abstract/FREE Full Text](#)
7. Baik W, Dunn W, Walter J. Epigenetic reprogramming in mammalian development. *Science* 2001;293:1089–93. [Abstract/FREE Full Text](#)
8. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr* 2009;21:243–51. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
9. Heightman TD. Therapeutic prospects for epigenetic modulation. *Expert Opin Ther Targets* 2011;15:729–40. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
10. Wright PJ. Epidemiology of stress and asthma: from constricting communities and fragile families to epigenetics. *Immunol Allergy Clin North Am* 2011;31:19–39. [CrossRef](#) [Medline](#) [Google Scholar](#)
11. Miller OJ, Schnedl W, Allen J, Erlanger BE. 5-Methylcytosine localized in mammalian constitutive heterochromatin. *Nature* 1974;251:636–37. [CrossRef](#) [Medline](#) [Google Scholar](#)
12. Voder JA, Walsh CP, Rector TH. Cytosine methylation and the ecology of intragenomic parasites. *Trends Genet* 1997;13:335–40. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002;3:415–28. [Medline](#) [Web of Science](#) [Google Scholar](#)
14. Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev* 2002;16:6–21. [FREE Full Text](#)
15. Chen PZ, Patterson H, Beard C, Jackson-Crueby J, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. *Nature* 1998;395:89–93. [CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
16. Eden A, Gaudet F, Washmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* 2003;300:455. [FREE Full Text](#)
17. Gaudet F, Hodgson IG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. *Science* 2003;300:489–92. [Abstract/FREE Full Text](#)

18. Laird PW. Cancer epigenetics. *Hum Mol Genet* 2005;(Spec No 1):R65–76.
[Google Scholar](#)
19. Houck CM, Binehart EP, Schmid CW. A ubiquitous family of repeated DNA sequences in the human genome. *J Mol Biol* 1979;132:289–306.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
20. Yang AS, Feterico MP, Doshi K, Kondo Y, Taiara EH, Isea IP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32:e38.
[Abstract/FREE Full Text](#)
21. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33:6823–36.
[Abstract/FREE Full Text](#)
22. Zhu ZZ, Hou J, Rollati V, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. *Int J Epidemiol* 2012;41:126–39.
[Abstract/FREE Full Text](#)
23. Choi JY, James SR, Link PA, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. *Carcinogenesis* 2009;30:1889–97.
[Abstract/FREE Full Text](#)
24. Groniger F, Weber R, Heil O, et al. Aging and chronic sun exposure cause distinct epigenetic changes in human skin. *PLoS Genet* 2010;6:e1000971.
[CrossRef](#) [Medline](#) [Google Scholar](#)
25. Dashmukh BS, Ostrup O, Ostrup E, et al. DNA methylation in porcine preimplantation embryos developed *in vivo* and produced by *in vitro* fertilization, parthenogenetic activation and somatic cell nuclear transfer. *Epigenetics* 2011;6:177–87.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
26. Anier K, Malinovicaja K, Anjum-Helm A, Zharkovskiy A, Kalda A. DNA methylation regulates cocaine-induced behavioral sensitization in mice. *Neuropsychopharmacology* 2010;35:2450–61.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
27. Orta MI, Dominguez J, Pastor N, Cortes E, Mateos S. The role of the DNA hypermethylation agent Budesonide in the decatenating activity of DNA topoisomerase II. *Mutat Res* 2010;694:45–52.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
28. Iriary BA, Ladd, Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. *Nat Genet* 2009;41:178–86.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
29. Shakhzian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* 2007;76:75–100.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
30. Suganuma T, Workman JL. Crosstalk among Histone Modifications. *Cell* 2008;135:604–07.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
31. Zhang YC, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. *Med Res Rev* 2008;28:645–87.
[CrossRef](#) [Medline](#) [Google Scholar](#)
32. Kouzarides T. Chromatin modifications and their function. *Cell* 2007;128:693–705.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
33. Luger K, Mader AW, Richmond RK, Sargent DE, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* 1997;389:251–60.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
34. Glizak MA, Seto E. Histone deacetylases and cancer. *Oncogene* 2007;26:5420–32.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
35. Steiner DF, Berger SI. Acetylation of histones and transcription-related factors. *Microbiol Mol Biol Rev* 2000;64:435–59.
[Abstract/FREE Full Text](#)
36. Cross WD, Seto E. Histone deacetylases, transcriptional control, and cancer. *J Cell Physiol* 2000;184:1–16.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
37. Wang Z, Zeng C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat Genet* 2008;40:897–903.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

38. Kleene DL, Zhang Y. Regulation of histone methylation by demethylation and demethylation. *Nat Rev Mol Cell Biol* 2007;8:307–18.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
39. Martin C, Zhang Y. The diverse functions of histone lysine methylation. *Nat Rev Mol Cell Biol* 2005;6:838–49.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
40. Wycicka J, Allie CD, Conrad S. Histone arginine methylation and its dynamic regulation. *Front Biosci* 2006;11:344–55.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
41. Meisner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature* 2008;454:766–70.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
42. Singh SK, Bal Bhadra M, Gireschick HJ, Bhadra H. MicroRNAs—micro in size but macro in function. *FEBS J* 2008;275:4929–44.
[CrossRef](#) [Medline](#) [Google Scholar](#)
43. Matkovich SJ, Van Rooyen DL, Eschenbacher WH, Dorn GW. 2nd. DISC DNA sequencing for context-specific identification of in vivo microRNA targets. *Circ Res* 2010;108:18–26.
[Medline](#) [Web of Science](#) [Google Scholar](#)
44. Williams AE. Functional aspects of animal microRNAs. *Cell Mol Life Sci* 2008;65:545–62.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
45. Huang Y, Shen XL, Zou Q, Wang SP, Tang SM, Zhang CZ. Biological functions of microRNAs: a review. *J Physiol Biochem* 2011;67:129–39.
[CrossRef](#) [Medline](#) [Google Scholar](#)
46. Ying SY, Chang DC, Lin SJ. The microRNA (miRNA): overview of the RNA genes that modulate gene function. *Mol Biotechnol* 2008;38:257–68.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
47. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat Rev Genet* 2004;5:396–400.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
48. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. *Int J Biochem Cell Biol* 2009;41:87–95.
[CrossRef](#) [Medline](#) [Google Scholar](#)
49. Backes C, Meese E, Lenhof HP, Keller A. A dictionary on microRNAs and their putative target pathways. *Nucleic Acids Res* 2010;38:4476–86.
[Abstract/FREE Full Text](#)
50. Ho J, Fivercoat H, Wang J, Pasinetti GM. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. *Exp Gerontol* 2010;45:15–22.
[CrossRef](#) [Medline](#) [Google Scholar](#)
51. Provost P. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. *Aging* 2010;2:166–69.
[Medline](#) [Web of Science](#) [Google Scholar](#)
52. Provost P. MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases. *Brain Res* 2010;1338:58–66.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
53. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. *J Cardiovasc Transl Res* 2010;3:251–55.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
54. Montgomery RL, van Rooij F. MicroRNA regulation as a therapeutic strategy for cardiovascular disease. *Curr Drug Targets* 2010;11:936–42.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
55. Shen F, Diao Y, Wei C, Wu Z, Zhang J, Hu B. MicroRNAs target gene and signaling pathway by bioinformatics analysis in the cardiac hypertrophy. *Biochem Biophys Res Commun* 2010;397:380–85.
[CrossRef](#) [Medline](#) [Google Scholar](#)
56. Swannhedauw B, Delcambre C, Samuel H, Mehazza A, Cohen-Solal A. Molecular mechanisms in evolutionary cardiomyopathy failure. *Ann N Y Acad Sci* 2010;1188:58–67.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
57. Eshbi M, Croce CM, Galis CA. MicroRNAs in the ontogeny of leukemias and lymphomas. *Leuk Lymphoma* 2009;50:160–70.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
58. Garzon P, Croce CM. MicroRNAs in normal and malignant hematopoiesis. *Curr Opin Hematol* 2008;15:352–58.

[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

59. Olive V, Jiang J, He L. miR-17-02: a cluster of miRNAs in the midst of the cancer network. *Int J Biochem Cell Biol* 2010;42:1348–54.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
60. Marcucci G, Padmanabhan MD, Mrozek K, Bloomfield CD. MicroRNA expression in acute myeloid leukemia. *Curr Hematol Malig Rep* 2009;4:83–88.
[CrossRef](#) [Medline](#) [Google Scholar](#)
61. Motyckova C, Stone RM. The role of molecular tests in acute myelogenous leukemia treatment decisions. *Curr Hematol Malig Rep* 2010;5:109–17.
[CrossRef](#) [Medline](#) [Google Scholar](#)
62. Zhao H, Wang D, Du W, Gu D, Yang B. MicroRNA and leukemia: tiny molecule, great function. *Crit Rev Oncol Hematol* 2010;74:149–55.
[CrossRef](#) [Medline](#) [Google Scholar](#)
63. Chen J, Xu X. Diet, epigenetic, and cancer prevention. *Adv Genet* 2010;71:237–55.
[CrossRef](#) [Medline](#) [Google Scholar](#)
64. Garzon P, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. *Nat Rev Drug Discov* 2010;9:775–89.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
65. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. *Br J Cancer* 2010;103:1144–48.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
66. Mathers JC, Strathdee C, Balton CL. Induction of epigenetic alterations by dietary and other environmental factors. *Adv Genet* 2010;71:3–39.
[CrossRef](#) [Medline](#) [Google Scholar](#)
67. Howard HU. Human health and heavy metals exposure. In: McCally M, editor. *Life Support: The Environment and Human Health*. Boston: Massachusetts Institute of Technology; 2002.
[Google Scholar](#)
68. Hamdan NY, Emmrich E, Faher S, Lehmann I, Sack U. Alterations of TH1/TH2 reactivity by heavy metals: possible consequences include induction of autoimmune diseases. *Ann NY Acad Sci* 2007;1109:129–37.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
69. Waalkes MP. Cadmium carcinogenesis. *Mutat Res* 2003;533:107–20.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
70. Salnikow K, Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. *Chem Res Toxicol* 2008;21:28–44.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
71. Huang C, Ke Q, Costa M, Shi Y. Molecular mechanisms of arsenic carcinogenesis. *Mol Cell Biochem* 2004;255:57–66.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
72. Caloric D, Evangelou A. The role of oxidative stress in mechanisms of metal-induced carcinogenesis. *Crit Rev Oncol Hematol* 2002;42:93–103.
[Medline](#) [Web of Science](#) [Google Scholar](#)
73. Leonard SS, Bower H, Shi Y. Metal-induced toxicity, carcinogenesis, mechanisms and cellular responses. *Mol Cell Biochem* 2004;255:3–10.
[CrossRef](#) [Medline](#) [Google Scholar](#)
74. Monke TL, Yie P, Tikoo K, Lau SS. Pbc-induced histone modifications and their role in cell survival and cell death. *Drug Metab Rev* 2006;38:755–67.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
75. Donaldson K, Stone V, Rorm PL, et al. Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). *Free Radic Biol Med* 2003;34:1369–82.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
76. Gilmour PS, Rahman I, Donaldson K, MacNee W. Histone acetylation regulates epithelial IL-8 release mediated by oxidative stress from environmental particles. *Am J Physiol Lung Cell Mol Physiol* 2003;284:L533–40.
[Abstract/FREE Full Text](#)
77. Bahar JA, Slack EL, Weidhaas JR. miRNA modulation of the cellular stress response. *Future Oncol* 2008;4:289–98.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
78. Sakano K, Inagaki Y, Oikawa S, Hiraku Y, Kawanishi S. Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. *Mutat Res* 2004;565:35–44.
[Medline](#) [Google Scholar](#)

79. Galier D, Skjoda V, Barbauti A. Redox signaling and cancer: the role of "labile" iron. *Cancer Lett* 2008;266:21–29.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
80. Raichard IF, Schnakenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. *Biochem Biophys Res Commun* 2007;352:188–92.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
81. Raubrahim-Talaa I, Waterland PA, Styblo M, Arhanzar WF, Wahber MM, Waalkes MP. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. *Toxicol Appl Pharmacol* 2005;206:288–98.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
82. Coppin IE, Qu W, Waalkes MP. Interplay between cellular methyl metabolism and adaptive efflux during oncogenic transformation from chronic arsenic exposure in human cells. *J Biol Chem* 2008;283:19342–50.
[Abstract/FREE Full Text](#)
83. Zhao CO, Young MP, Diwan RA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. *Proc Natl Acad Sci USA* 1997;94:10907–12.
[Abstract/FREE Full Text](#)
84. Chen H, Li S, Liu J, Diwan RA, Barrett IC, Waalkes MP. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. *Carcinogenesis* 2004;25:1779–86.
[Abstract/FREE Full Text](#)
85. Okonji PS, Yu BC, Maronpot PB, Ernoies JB. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. *Carcinogenesis* 2002;23:777–85.
[Abstract/FREE Full Text](#)
86. Uthur EO, Davis C. Dietary arsenic affects dimethylhydrazine-induced aberrant crypt formation and hepatic global DNA methylation and DNA methyltransferase activity in rats. *Biol Trace Elem Res* 2005;103:133–45.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
87. Yie Y, Trauba KI, Liu J, Waalkes MP, Carmoler DP. Pharmacokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in *v-Ha-ras* transgenic (Tg.AC) mice. *Environ Health Perspect* 2004;112:1255–63.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
88. Majumdar S, Chanda S, Ganguli B, Mazumder DN, Lahiri S, Dasgupta UR. Arsenic exposure induces genomic hypermethylation. *Environ Toxicol* 2010;25:315–18.
[Medline](#) [Google Scholar](#)
89. Bilenor IB, Liu Y, Akbar H, et al. Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults. *Am J Clin Nutr* 2007;86:1179–86.
[Abstract/FREE Full Text](#)
90. Chai CY, Huang YC, Hung WC, Kang WY, Chen WT. Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. *Toxicol Lett* 2007;173:48–56.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
91. Fu HY, Shen LZ. Hypermethylation of CpG island of p16 gene and arsenic trioxide induced p16 gene demethylation in multiple myeloma. *Zhonghua Nei Ke Za Zhi* 2005;44:411–14.
[Medline](#) [Google Scholar](#)
92. Jensen TJ, Novak B, Ehlis KE, Gandolfi AJ, Euteneier BW. Epigenetic remodeling during arsenical-induced malignant transformation. *Carcinogenesis* 2008;29:1500–508.
[Abstract/FREE Full Text](#)
93. Mass MI, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. *Mutat Res* 1997;386:263–77.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
94. Chen H, Liu J, Zhao CO, Diwan RA, Merrick RA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. *Toxicol Appl Pharmacol* 2001;175:260–68.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
95. Takahashi M, Barrett IC, Teitelui T. Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into a neoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters. *Int J Cancer* 2002;99:629–34.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

96. Cui Y, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. *Toxicol Sci* 2006;91:372–81.
[Abstract/FREE Full Text](#)
97. Waalkes MP, Liu J, Chen H, et al. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. *J Natl Cancer Inst* 2004;96:466–74.
[Abstract/FREE Full Text](#)
98. Chanda S, Dasgupta HR, Guhamazumder D, et al. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. *Toxicol Sci* 2006;89:431–37.
[Abstract/FREE Full Text](#)
99. Chen WT, Hung WC, Kang MY, Huang YC, Chai CY. Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. *Histopathology* 2007;51:785–92.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
100. Marcit CL, Karagas MR, Danase H, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. *Carcinogenesis* 2006;27:112–16.
[Abstract/FREE Full Text](#)
101. Zhang AH, Bin HH, Pan YL, Yi YC. Analysis of p16 gene mutation, deletion and methylation in patients with arseniasis produced by indoor unventilated-stove coal usage in Guizhou, China. *J Toxicol Environ Health A* 2007;70:970–75.
[CrossRef](#) [Medline](#) [Google Scholar](#)
102. Ronchaji W, Walsh M, Cummings M, Cheneyiv-Trench C. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. *Arch Dermatol* 2000;136:195–98.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
103. Arrigo AP. Acetylation and methylation patterns of core histones are modified after heat or arsenite treatment of *Drosophila* tissue culture cells. *Nucleic Acids Res* 1983;11:1389–404.
[Abstract/FREE Full Text](#)
104. Jo WL, Pan Y, Chu F, et al. Acetylated H4K16 by MVST1 protects H9Cec2 cells from arsenic toxicity and is decreased following chronic arsenic exposure. *Toxicol Appl Pharmacol* 2009;241:294–302.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
105. Li J, Chen P, Singdeeva N, et al. Arsenic trioxide promotes histone H3 phosphorylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. *J Biol Chem* 2002;277:49504–10.
[Abstract/FREE Full Text](#)
106. Li J, Corcoran M, Barnes J, Liu Y. Tumor promoter arsenite stimulates histone H3 phosphorylation of proto-oncogenes *c-fos* and *c-jun* chromatin in human diploid fibroblasts. *J Biol Chem* 2003;278:13183–91.
[Abstract/FREE Full Text](#)
107. Ramirez T, Brocher J, Stepper H, Hoek P. Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. *Chromosoma* 2008;117:147–57.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
108. Desrosiers P, Tanguay BM. Further characterization of the posttranslational modifications of core histones in response to heat and arsenite stress in *Drosophila*. *Biochem Cell Biol* 1986;64:750–57.
[Medline](#) [Google Scholar](#)
109. Desrosiers P, Tanguay BM. Methylation of *Drosophila* histones at proline, lysine, and arginine residues during heat shock. *J Biol Chem* 1988;263:4686–92.
[Abstract/FREE Full Text](#)
110. Zhou Y, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. *Carcinogenesis* 2008;29:1831–36.
[Abstract/FREE Full Text](#)
111. Zhou Y, Li Q, Arita A, Sun H, Costa M. Effects of nickel chromate and arsenite on histone 3 lysine methylation. *Toxicol Appl Pharmacol* 2009;236:78–84.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
112. Zukova TA, Zhu F, Lu C, et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AY prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. *Clin Cancer Res* 2006;12:6884–93.
[Abstract/FREE Full Text](#)
113. Marcit CL, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. *Cancer Res* 2006;66:10843–48.
[Abstract/FREE Full Text](#)
114. Binet F, Antoine F, Girard D. Interaction between arsenic trioxide and human

- primary cells: emphasis on human cells of myeloid origin. *Inflamm Allergy Drug Targets* 2009;8:21–27.
[CrossRef](#) [Medline](#) [Google Scholar](#)
115. Cao Y, Yu SL, Wang Y, Guo CY, Ding Q, An PH. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. *Tumour Biol* 2011;32:179–88.
[CrossRef](#) [Medline](#) [Google Scholar](#)
116. Lee YW, Klein CR, Kargacin R, et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation – a new model for epigenetic carcinogens. *Mol Cell Biol* 1995;15:2547–57.
[Abstract/FREE Full Text](#)
117. Lee YW, Klein CR, Kargacin R, et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. *Mol Cell Biol* 1995;15:2547–57.
[Abstract/FREE Full Text](#)
118. Klein CR, Conway K, Wang YW, et al. Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. *Science* 1991;251:796–99.
[Abstract/FREE Full Text](#)
119. Govindarajan R, Kjafer B, Miller MS, et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. *Mol Med* 2002;8:1–8.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
120. Karaczyn AA, Colebiowski E, Kasprzak KS. Truncation, deamidation, and oxidation of histone H2B in cells cultured with nickel(II). *Chem Res Toxicol* 2005;18:1934–42.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
121. Karaczyn A, Ivanov S, Reynolds M, Zhitkovich A, Kasprzak KS, Salnikow K. Acetate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. *J Cell Biochem* 2006;97:1025–35.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
122. Broday L, Peng W, Kuo MH, Salnikow K, Zeroddu M, Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. *Cancer Res* 2000;60:238–41.
[Abstract/FREE Full Text](#)
123. Chen H, Ke Q, Kluz T, Yan Y, Costa M. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. *Mol Cell Biol* 2006;26:3728–37.
[Abstract/FREE Full Text](#)
124. Ke QD, Davidson T, Chen HR, Kluz T, Costa M. Alterations of histone modifications and transgene silencing by nickel chloride. *Carcinogenesis* 2006;27:1481–88.
[Abstract/FREE Full Text](#)
125. Colebiowski E, Kasprzak KS. Inhibition of core histones acetylation by carcinogenic nickel(II). *Mol Cell Biochem* 2005;279:133–39.
[CrossRef](#) [Medline](#) [Google Scholar](#)
126. Klein CR, Costa M. DNA methylation, heterochromatin and epigenetic carcinogens. *Mutat Res–Rev Mutat Res* 1997;386:163–80.
[Google Scholar](#)
127. Klein CR, Conway K, Wang YW, et al. Senescence of nickel-transformed cells by an x-chromosome – possible epigenetic control. *Science* 1991;251:796–99.
[Abstract/FREE Full Text](#)
128. Yan Y, Kluz T, Zhang B, Chen HR, Costa M. Analysis of specific lysine histone H3 and H4 acetylation and methylation status in clones of cells with a gene silenced by nickel exposure. *Toxicol Appl Pharmacol* 2003;190:272–77.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
129. Zhang QW, Salnikow K, Kluz T, Chen HC, Su WC, Costa M. Inhibition and reversal of nickel-induced transformation by the histone deacetylase inhibitor trichostatin A. *Toxicol Appl Pharmacol* 2003;192:201–11.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
130. Broday L, Peng W, Kuo MH, Salnikow K, Zeroddu M, Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. *Cancer Res* 2000;60:238–41.
[Abstract/FREE Full Text](#)
131. Colebiowski E, Kasprzak KS. Inhibition of core histones acetylation by carcinogenic nickel(II). *Mol Cell Biochem* 2005;279:133–39.
[CrossRef](#) [Medline](#) [Google Scholar](#)
132. Ke Q, Li Q, Ellen TP, Sun H, Costa M. Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK–MAPK pathway. *Carcinogenesis* 2008;29:1276–81.
[Abstract/FREE Full Text](#)
133. Huang D, Zhang Y, Qi Y, Chen C, Ji W. Global DNA hypomethylation, rather than

- reactive oxygen species (ROS) a potential facilitator of cadmium-stimulated K562 cell proliferation. *Toxicol Lett* 2008;179:43–47.
[CrossRef](#) [Medline](#) [Google Scholar](#)
134. Takiguchi M, Achanzar WE, Ou W, Li C, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. *Exp Cell Res* 2003;286:355–65.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
135. Tellez-Plaza M, Navas-Arrien A, Crainiceanu CM, Guallar F. Cadmium exposure and hypertension in the 1990–2004 National Health and Nutrition Examination Survey (NHANES). *Environ Health Perspect* 2008;116:51–56.
[Medline](#) [Web of Science](#) [Google Scholar](#)
136. Bhatnagar A. Environmental cardiology – Studying mechanistic links between pollution and heart disease. *Circulation Res* 2006;99:692–705.
[Abstract/FREE Full Text](#)
137. Rollati V, Marinelli B, Annetoli P, et al. Exposure to metal-rich particulate matter modifies the expression of candidate microRNAs in peripheral blood leukocytes. *Environ Health Perspect* 2010;118:763–68.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
138. Williams AE, Barry MM, Moschos SA, Larner-Svensson HM, Lindeau MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. *Biochem Soc Trans* 2008;36(Pt 6):1211–15.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
139. Pilener IR, Lazarus DJ, Nam DH, et al. Mercury-associated DNA hypomethylation in polar bear brains via the Illuminometric Methylation Assay: a sensitive method to study epigenetics in wildlife. *Mol Ecol* 2010;19:307–14.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
140. Arai Y, Okano J, Yagi S, et al. Epigenetic Assessment of environmental chemicals detected in maternal peripheral and cord blood samples. *J Reprod Dev* 2011;57:507–17.
[CrossRef](#) [Medline](#) [Google Scholar](#)
141. Wright PD, Schwartz J, Wright BL, et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. *Environ Health Perspect* 2010;118:790–95.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
142. Pilener IR, Hu H, Ettinger A, et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 2009;117:1466–71.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
143. Kondo K, Takahashi Y, Hirose Y, et al. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. *Lung Cancer* 2006;53:295–302.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
144. Takahashi Y, Kondo K, Hirose T, et al. Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. *Mol Carcinogenesis* 2005;42:150–58.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
145. Erquin H, Fortier M, Fournier M. Toxic effects of various pollutants in 11B7501 lymphoma R cell line from harbour seal (*Phoca vitulina*). *Toxicology* 2010;270:66–76.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
146. Annetoli P, Catalani S. Mechanisms of action for metallic elements and their species classified carcinogen R 45 and R 49 by EU. *G Ital Med Lav Ergon* 2008;30:382–91.
[Medline](#) [Google Scholar](#)
147. Schreckenburger M, Talacka C, Buzs A. Chromium cross-links histone deacetylase 1, DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. *Mol Cell Biol* 2007;27:7089–101.
[Abstract/FREE Full Text](#)
148. Sun H, Zhou Y, Chen H, Li Q, Coats M. Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. *Toxicol Appl Pharmacol* 2009;237:258–66.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
149. Pogus AI, Li YY, Cui JC, et al. Characterization of an NE-kappaB-regulated miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells. *J Inorg Biochem* 2009;103:1591–95.
[CrossRef](#) [Medline](#) [Google Scholar](#)
150. Lukiw WI, Pogus AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. *J Inorg Biochem* 2007;101:1265–69.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

151. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683–92.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
152. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. *Cancer Metastasis Rev* 2010;29:181–206.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
153. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med* 2009;361:2449–60.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
154. Anway MD, Cunn AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* 2005;308:1466–69.
[Abstract/FREE Full Text](#)
155. Guerrero-Rosagna C, Sattler M, Tucker R, Skinner MK. Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome. *PLoS One* 2010;5:e13100.
[CrossRef](#) [Medline](#) [Google Scholar](#)
156. Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors. *Endocrinology* 2006;147 6 Suppl:S43–49.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
157. Zama AM, Uzumcu M. Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. *Endocrinology* 2009;150:4681–91.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
158. Tao J, Yang S, Yie M, Kramer PM, Pereira MA. Hypomethylation and overexpression of *c-jun* and *c-myc* protooncogenes and increased DNA methyltransferase activity in dichloroacetic and trichloroacetic acid-promoted mouse liver tumors. *Cancer Lett* 2000;158:185–93.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
159. Tao J, Yang S, Yie M, Kramer PM, Pereira MA. Effect of trichloroethylene and its metabolites, dichloroacetic acid and trichloroacetic acid, on the methylation and expression of *c-jun* and *c-myc* protooncogenes in mouse liver: prevention by methionine. *Toxicol Sci* 2000;54:399–407.
[Abstract/FREE Full Text](#)
160. Hathaway C, Proctor N, Hughes J, Fiechman M, Proctor And Hughes' *Chemical Hazards of the Workplace*. New York: Van Nostrand Reinhold; 1991.
[Google Scholar](#)
161. Buziński JA, Baccarelli A, Bellati V, Tarantini L, Moora JE, Bonfeldt, Jørgensen EC. Global DNA hypomethylation is associated with high serum persistent organic pollutants in Greenlandic Inuit. *Environ Health Perspect* 2008;116:1547–52.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
162. Kim KY, Kim DS, Lee SK, et al. Association of low-dose exposure to persistent organic pollutants with global DNA hypomethylation in healthy Koreans. *Environ Health Perspect* 2010;118:370–74.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
163. Alavanja MC, Renner MR. Pesticides and human cancers. *Cancer Invest* 2005;23:700–11.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
164. Waichenthal S, Meese C, Chan B. A review of pesticide exposure and cancer incidence in the Agricultural Health Study cohort. *Environ Health Perspect* 2010;118:1117–25.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
165. Alavanja MC, Ward MH, Reynolds P. Carcinogenicity of agricultural pesticides in adults and children. *J Agromedicine* 2007;12:39–56.
[CrossRef](#) [Medline](#) [Google Scholar](#)
166. Baccil KL, Malik C, Sanborn M, Cole DC, Kaur IS, Kerr KL. Cancer health effects of pesticides: systematic review. *Can Fam Physician* 2007;53:1704–11.
[Abstract/FREE Full Text](#)
167. Koutros S, Alavanja MC, Lubin JH, et al. An update of cancer incidence in the Agricultural Health Study. *J Occup Environ Med* 2010;52:1098–105.
[CrossRef](#) [Medline](#) [Google Scholar](#)
168. Waggoner JK, Kullman CI, Henneberger PK, et al. Mortality in the agricultural health study, 1993–2007. *Am J Epidemiol* 2011;173:71–83.
[Abstract/FREE Full Text](#)
169. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. *Mol Pharmacol* 2010;77:621–32.
[Abstract/FREE Full Text](#)
170. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental

neurotoxic pecticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. *Mol Pharmacol* 2010;77:621–32.

[Abstract/FREE Full Text](#)

171. Baccarelli A, Cascano PA, Litonjua A, et al. Cardiac autonomic dysfunction – effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms. *Circulation* 2008;117:1802–09.
[Abstract/FREE Full Text](#)
172. Jardim MI, Eny BC, Ibanez I, Dailey I, Diaz-Sanchez D. Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways. *Environ Health Perspect* 2009;117:1745–51.
[Medline](#) [Web of Science](#) [Google Scholar](#)
173. Tarantini L, Bonzini M, Apostoli P, et al. Effects of particulate matter on genomic DNA methylation content and iNOS promoter methylation. *Environ Health Perspect* 2009;117:217–22.
[Medline](#) [Web of Science](#) [Google Scholar](#)
174. Yauk C, Polyzos A, Bowen-Carroll A, et al. Germ-line mutations, DNA damage and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. *Proc Natl Acad Sci USA* 2008;105:605–10.
[Abstract/FREE Full Text](#)
175. Liu J, Ballaney M, Al-Alem H, et al. Combined inhaled diesel exhaust particles and allergen exposure alter methylation of T helper genes and IgE production in vivo. *Toxicol Sci* 2008;102:76–81.
[Abstract/FREE Full Text](#)
176. Parera F, Tang WY, Herbstman J, et al. Relation of DNA methylation of 5'-CpG island of ACSI3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. *PLoS One* 2009;4:e4488.
[CrossRef](#) [Medline](#) [Google Scholar](#)
177. Cantone J, Nordin E, Hou J, et al. Effects of Inhalable Metal-Rich Air Particles on Histone H3K4 Dimethylation and H3K9 Acetylation in a Cross-sectional Study of Steel Workers. *Environ Health Perspect* 2011;119:964–9.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
178. Ballati V, Marinelli B, Apostoli P, et al. Exposure to metal rich particulate matter modifies the expression of candidate micrnas in peripheral blood leukocytes. *Environ Health Perspect* 2010.
[Google Scholar](#)
179. Smith MT. Advances in understanding benzene health effects and susceptibility. *Annu Rev Public Health* 2010;31:133–48. 2 p following 148.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
180. Pinky PA, Hornung PW, Silver SB, Teang CY. Benzene exposure and hematopoietic mortality: a long-term epidemiologic risk assessment. *Am J Ind Med* 2002;42:474–80.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
181. Goldstein BD. Benzene toxicity. *Occup Med* 1988;3:541–54.
[Medline](#) [Google Scholar](#)
182. Whitworth KW, Sumanek E, Coker AL. Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995–2004. *Environ Health Perspect* 2008;116:1576–80.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
183. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. *IARC Monogr Eval Carcinog Risks Hum Suppl* 1987;7:1–440.
[Medline](#)
184. Richardson DB. Temporal variation in the association between benzene and leukemia mortality. *Environ Health Perspect* 2008;116:370–74.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
185. CDC. Facts About Benzene, 2005. Available from: <http://www.bt.cdc.gov/agent/benzene/basics/facts.asp>.
186. Ballati V, Baccarelli A, Hou J, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. *Cancer Res* 2007;67:876–80.
[Abstract/FREE Full Text](#)
187. Ji Z, Zhang J, Peng Y, Ren Y, McHale CM, Smith MT. A comparison of the cytogenetic alterations and global DNA hypermethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide. *Leukemia* 2010;24:986–91.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
188. Gao A, Zuo Y, Liu Q, Lu Y, Cuo W, Tian J. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression. *Toxicol Lett* 2010;195:114–18.

[CrossRef](#) [Medline](#) [Google Scholar](#)

189. Kari PA, Ho SM, Hunt DA, Knudsen KE, Soto AM, Prins GS. An evaluation of evidence for the carcinogenic activity of bisphenol A. *Reprod Toxicol* 2007;24:240–52.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
190. Ho SM, Tang WY, de Frausto IR, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res* 2006;66:5624–32.
[Abstract/FREE Full Text](#)
191. vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. *Environ Health Perspect* 2005;113:926–33.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
192. Dolinsky DC, Huang D, Jirtle RL. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. *Proc Natl Acad Sci USA* 2007;104:13056–61.
[Abstract/FREE Full Text](#)
193. Waterland PA. Is epigenetics an important link between early life events and adult disease? *Horm Res* 2009;71 Suppl 1:13–16.
[CrossRef](#) [Medline](#) [Google Scholar](#)
194. Bromer JG, Zhou Y, Taylor MB, Doherty J, Taylor HS. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB J* 2010;24:2273–80.
[Abstract/FREE Full Text](#)
195. Wang YL, Heu BV, Livanarachchi S, et al. Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. *Toxicol Appl Pharmacol* 2010;248:111–21.
[CrossRef](#) [Medline](#) [Google Scholar](#)
196. Avissar, Whiting M, Voica KB, Uhl KM, et al. Bisphenol A exposure leads to specific microRNA alterations in placental cells. *Reprod Toxicol* 2010;29:401–06.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
197. Raedananari SP, Taylor PT, Rui P, Wang F, Nickerson DW, Hankinson O. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. *Mol Pharmacol* 2010;78:608–16.
[Abstract/FREE Full Text](#)
198. Wang J, Zhao XY, Liu H, et al. The role of insulin-like growth factor-2 gene differentially methylated regions in TCDD-induced malformation. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2007;24:162–66.
[Medline](#) [Google Scholar](#)
199. McClure EA, North CM, Kaminski NE, Goodman II. Changes in DNA methylation and gene expression during 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced suppression of the lipopolysaccharide (LPS)-stimulated IgM response in splenocytes. *Toxicol Sci* 2011;120:339–48.
[Abstract/FREE Full Text](#)
200. Elvakim E, Sithon E, Faerman A, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. *Cancer Res* 2010;70:8077–87.
[Abstract/FREE Full Text](#)
201. Raller HP, Tiemeier K. Use of liquid chromatography/tandem mass spectrometry to detect distinctive indicators of in situ DDY transformation in contaminated groundwater. *Environ Sci Technol* 2002;36:2060–66.
[CrossRef](#) [Google Scholar](#)
202. Zhang B, Bao Y. DDY induces aberrant expression of microRNAs in mouse brain and liver. *Environ Health Perspect* 2009;117:231–40.
[Medline](#) [Web of Science](#) [Google Scholar](#)
203. Jaitman CI. DES exposure and the aging woman: mothers and daughters. *Curr Womens Health Rep* 2002;2:390–93.
[Medline](#) [Google Scholar](#)
204. Palmer JB, Hatch EE, Rosenbergl CI, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). *Cancer Causes Control* 2002;13:753–58.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
205. Heu BV, Deatherage DE, Rodriguez BA, et al. Xenestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. *Cancer Res* 2009;69:5936–45.
[Abstract/FREE Full Text](#)
206. Manes F, Marocchini O, Prigent AE, Foullet P. Increased methylation of chloroform extractable products and CTP: cholinephosphate cytidylyltransferase in brain membrane preparations from triethyltin-intoxicated rats. *Pharmacol Toxicol*

- 1989;65:302–05.
[Medline](#) [Web of Science](#) [Google Scholar](#)
207. Pereira MA, Kramer PM, Conran PR, Tao I. Effect of chloroform on dichloroacetic acid and trichloroacetic acid-induced hypomethylation and expression of the *C-myc* gene and on their promotion of liver and kidney tumors in mice. *Carcinogenesis* 2001;22:1511–19.
[Abstract/FREE Full Text](#)
208. Coffin IC, Ge R, Yang S, Kramer PM, Tao I, Pereira MA. Effect of trihalomethanes on cell proliferation and DNA methylation in female B6C3F1 mouse liver. *Toxicol Sci* 2000;58:243–52.
[Abstract/FREE Full Text](#)
209. Chlorinated drinking-water. IARC Monogr Eval Carcinog Risks Hum 1991;52:45–141.
[Medline](#)
210. Haden PC, Miller IW. Chlorinated acids and chloral in drinking water. *J Am Water Works Assoc* 1983;75:524–27.
[Web of Science](#) [Google Scholar](#)
211. Coleman WF, Munch IW, Kayler WH, Streicher PB, Binchand HP, Meier JB. Gas chromatography/mass spectroscopy analysis of mutagenic extracts of aqueous chlorinated humic acid. A comparison of the by-products to drinking water contaminants. *Environ. Sci. Technol.* 1984;18:674–78.
[CrossRef](#) [Google Scholar](#)
212. Shi J, Wu J. Epigenetic regulation in mammalian preimplantation embryo development. *Reprod Biol Endocrinol* 2009;7:59–69.
[CrossRef](#) [Medline](#) [Google Scholar](#)
213. Morgan HD, Sutherland HC, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. *Nat Genet* 1999;23:314–18.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
214. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc Natl Acad Sci USA* 2008;105:17046–49.
[Abstract/FREE Full Text](#)
215. Tobi EW, Lumey LH, Talens PP, et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. *Hum Mol Genet* 2009;18:4046–53.
[Abstract/FREE Full Text](#)
216. Heijmans BT, Tobi EW, Lumey LH, Slagboom PE. The epigenome: archive of the prenatal environment. *Epigenetics* 2009;4:526–31.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
217. Terry MB, Ferris JS, Bilney B, et al. Genomic DNA methylation among women in a multiethnic New York City birth cohort. *Cancer Epidemiol Biomarkers Prev* 2008;17:2306–10.
[Abstract/FREE Full Text](#)
218. Flom J, Ferris J, Gonzalez K, Santella P, Terry M. Prenatal tobacco smoke exposure and genome-wide methylation in adulthood. *Cancer Epidemiol Biomarkers Prev* 2011;20:720–21.
[Abstract/FREE Full Text](#)
219. Guerrero-Preston R, Goldman LR, Rrahi-Miaville P, et al. Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. *Epigenetics* 2010;5:539–46.
[CrossRef](#) [Medline](#) [Google Scholar](#)
220. Maccani MA, Aviccar, Whiting M, Banister CE, McConnial P, Badbury JE, Marcit CL. Maternal cigarette smoking during pregnancy is associated with downregulation of miR-16, miR-21, and miR-146a in the placenta. *Epigenetics* 2010;5:583–89.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
221. Minard ME, Jain AK, Barton MC. Analysis of epigenetic alterations to chromatin during development. *Genesis* 2009;47:559–72.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
222. Balton CL, Davey Smith G. Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. *PLoS Med* 2010;7:e1000356.
[CrossRef](#) [Medline](#) [Google Scholar](#)
223. Genelatti S, Gallo V, Porta M, Khoury MI, Vineis P. Assessing causal relationships in genomics: From Bradford-Hill criteria to complex gene-environment interactions and directed acyclic graphs. *Emerg Themes Epidemiol* 2011;8:5–22.
[CrossRef](#) [Medline](#) [Google Scholar](#)
224. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. *Curr Opin Genet Dev* 2005;15:490–95.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

225. Chuang IC, Jones PA. Epigenetics and microRNAs. *Pediatr Res* 2007;61(5 Pt 2):24R–29R.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
226. Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. *Carcinogenesis* 2004;25:413–17.
[Abstract/FREE Full Text](#)
227. Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. *Int J Cancer* 2007;121:1724–28.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
228. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. *Leukemia* 2006;20:1445–48.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
229. Deng G, Nguyen A, Tanaka H, et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. *Int J Cancer* 2006;118:2999–3005.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
230. Brothman AR, Swanson G, Maxwell TM, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? *Cancer Genet Cytogenet* 2005;156:31–36.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
231. Shimabukuro M, Sasaki T, Imamura A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. *J Psychiatr Res* 2007;41:1042–46.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
232. Bagnyukova TV, Luzhna LI, Pogribny IP, Lushchak VI. Oxidative stress and antioxidant defenses in goldfish liver in response to short-term exposure to arsenite. *Environ Mol Mutagen* 2007;48:658–65.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
233. Pilsner JR, Liu X, Ahsan H, et al. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. *Environ Health Perspect* 2009;117:254–60.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
234. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2' deoxycytidine to increase SPARC expression and improve therapy response. *British J Cancer* 2008;98:1810–19.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
235. Alemayehu A, Sebova K, Fridrichova I. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients. *Genes Chrom Cancer* 2008;47:906–14.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
236. Norrie MWA, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW, Ward RL. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. *Dis Colon Rectum* 2002;45:674–80.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
237. Minardi D, Lucarini G, Filosa A, et al. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. *J Cell Mol Med* 2009;13:2115–21.
[CrossRef](#) [Medline](#) [Google Scholar](#)
238. Schafer E, Irizarry R, Negi S, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. *Blood* 2010;115:4798–809.
[Abstract/FREE Full Text](#)
239. Owen HC, Giedl J, Wild PJ, et al. Low frequency of epigenetic events in urothelial tumors in young patients. *J Urol* 2010;184:459–63.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
240. Qian J, Yao DM, Lin J, et al. Alteration of methylation status of death-associated protein kinase (dapk) gene promoter in patients with acute myeloid leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2010;18:1390–94.
[Medline](#) [Google Scholar](#)
241. Laytragoon-Lewin N, Chen F, Castro J, et al. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients. *Anticancer Res* 2010;30:4643–48.
[Abstract/FREE Full Text](#)
242. Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. *Oral Oncol*

2011;47:104–7.

[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

243. Hafner N, Diebold H, Jansen L, Hoppe I, Durst M, Runnebaum IB. Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. *Gynecol Oncol* 2011;121:224–9.
[CrossRef](#) [Medline](#) [Google Scholar](#)
244. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. *Epigenetics* 2011;6:307–16.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
245. Ben Ayed-Guerfali D, Benhaj K, Khabir A, et al. Hypermethylation of tumor-related genes in tunisian patients with gastric carcinoma: Clinical and biological significance. *J Surg Oncol* 2011;103:687–94.
[CrossRef](#) [Medline](#) [Google Scholar](#)
246. Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. *Oncol Rep* 2011;25:513–18.
[Medline](#) [Google Scholar](#)
247. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. *Cancer Lett* 2011;303:21–8.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
248. Hu SL, Kong XY, Cheng ZD, et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. *Tumori* 2010;96:726–33.
[Medline](#) [Web of Science](#) [Google Scholar](#)
249. Van der Auwera I, Bovie C, Svensson C, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. *BMC Cancer* 2010;10:97–104.
[CrossRef](#) [Medline](#) [Google Scholar](#)
250. Zhang C, Jin Y, Xu H, et al. Relationship between promoter methylation of p16, DAPK and RAR beta genes and the clinical data of non-small cell lung cancer. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2011;28:23–28.
[Medline](#) [Google Scholar](#)
251. Peng Z, Shan C, Wang H. Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2010;35:247–53.
[Medline](#) [Google Scholar](#)
252. Malhotra P, Kochhar R, Vaiphei K, Wig JD, Mahmood S. Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients. *World J Gastrointest Oncol* 2010;2:295–303.
[CrossRef](#) [Medline](#) [Google Scholar](#)
253. Poetsch M, Hemmerich M, Kakies C, et al. Alterations in the tumor suppressor gene p16 (INK4A) are associated with aggressive behavior of penile carcinomas. *Virchows Arch* 2011;458:221–29.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
254. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. *Urol Oncol* 2010. in press.
[Google Scholar](#)
255. Wang D, Wang J, Li Y, He Z, Zhang Y. The influence of anthracosis and p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcinoma. *Exp Mol Pathol* 2011;90:131–36.
[CrossRef](#) [Medline](#) [Google Scholar](#)
256. Zainuddin N, Kanduri M, Berglund M, et al. Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. *Leuk Res* 2011;35:438–43.
[CrossRef](#) [Medline](#) [Google Scholar](#)
257. Shaw R, Risk JM, Liloglou T. RE: P16 INK41 promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age dependent manner. Su et al. *Oral Oncol* 2010;46:734–39.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
258. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. *Int J Cancer* 2011;129:78–87.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
259. Hill VK, Hesson LB, Dansranjav T, et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. *Mol Cancer* 2010;9:51–63.
[CrossRef](#) [Medline](#) [Google Scholar](#)
260. Gronbaek K, Ralfkiaer U, Dahl C, et al. Frequent hypermethylation of DBC1 in

- malignant lymphoproliferative neoplasms. *Mod Pathol* 2008;21:632–38.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
261. Radpour R, Barekati Z, Haghighi MM, et al. Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. *Mod Pathol* 2010;23:763–72.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
262. Hanafusa T, Shinji T, Shiraha H, et al. Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. *BMC Cancer* 2005;5:9–19.
[CrossRef](#) [Medline](#) [Google Scholar](#)
263. Luo J, Li YN, Wang F, Zhang WM, Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. *Int J Biol Sci* 2010;6:784–95.
[Medline](#) [Google Scholar](#)
264. Fang JY, Zhu SS, Xiao SD, et al. Studies on the hypomethylation of c-myc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma. *J Gastroenterol Hepatol* 1996;11:1079–82.
[Medline](#) [Google Scholar](#)
265. Tsujiuchi T, Tsutsumi M, Sasaki Y, Takahama M, Konishi Y. Hypomethylation of CpG sites and c-myc gene overexpression in hepatocellular carcinomas, but not hyperplastic nodules, induced by a choline-deficient L-amino acid-defined diet in rats. *Jpn J Cancer Res* 1999;90:909–13.
[CrossRef](#) [Web of Science](#) [Google Scholar](#)
266. Shen L, Qui D, Fang J. Correlation between hypomethylation of c-myc and c-N-ras oncogenes and pathological changes in human hepatocellular carcinoma. *Zhonghua Zhong Liu Za Zhi* 1997;19:173–76.
[Medline](#) [Google Scholar](#)
267. Del Senno L, Maestri I, Piva R, et al. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. *J Urol* 1989;142:146–49.
[Medline](#) [Web of Science](#) [Google Scholar](#)
268. Rabiau N, Thiam MO, Satih S, et al. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. *In Vivo* 2009;23:387–91.
[Abstract/FREE Full Text](#)
269. Buckingham L, Penfield Faber L, Kim A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. *Int J Cancer* 2010;126:1630–39.
[Medline](#) [Web of Science](#) [Google Scholar](#)
270. Zhang A, Feng H, Yang G, et al. Unventilated indoor coal-fired stoves in Guizhou province, China: cellular and genetic damage in villagers exposed to arsenic in food and air. *Environ Health Perspect* 2007;115:653–8.
[Medline](#) [Web of Science](#) [Google Scholar](#)
271. Zhong CX, Mass MJ. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. *Toxicol Lett* 2001;122:223–34.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
272. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. *J Urol* 2008;180:1131–36.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
273. Jo WJ, Ren XF, Chu FX, et al. Acetylated H4K16 by MYST1 protects UROtsa cells from arsenic toxicity and is decreased following chronic arsenic exposure. *Toxicol Appl Pharmacol* 2009;241:294–302.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
274. Sayyed SG, Gaikwad AB, Lichtnekert J, et al. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. *Nephrol Dial Transplant* 2010;25:1811–17.
[Abstract/FREE Full Text](#)
275. Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K, Anders HJ. Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. *Am J Pathol* 2010;176:1079–83.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
276. Gao WM, Chadha MS, Kline AE, et al. Immunohistochemical analysis of histone H3 acetylation and methylation – evidence for altered epigenetic signaling following traumatic brain injury in immature rats. *Brain Res* 2006;1070:31–4.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
277. Zhao F, Chen Y, Zeng L, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. *Eur J*

- Pharmacol 2010;646:1–11.
[CrossRef](#) [Medline](#) [Google Scholar](#)
278. Seligson DB, Horvath S, McBrien MA, et al. Global Levels of Histone Modifications Predict Prognosis in Different Cancers. *Am J Pathol* 2009;174:1619–28.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
279. Arita A, Costa M. Epigenetics in metal carcinogenesis: Nickel, Arsenic, Chromium and Cadmium. *Metallomics* 2009;1:222–28.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
280. Chen MW, Hua KT, Kao HJ, et al. H3K9 Histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. *Cancer Res* 2010;70:7830–40.
[Abstract/FREE Full Text](#)
281. Yao JY, Zhang L, Zhang X, et al. H3K27 trimethylation is an early epigenetic event of p16(INK4a) silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. *J Biol Chem* 2010;285:18828–37.
[Abstract/FREE Full Text](#)
282. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. *Blood* 2010;115:3098–108.
[Abstract/FREE Full Text](#)
283. Porcedda P, Turinetto V, Brusco A, et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. *Cytometry A* 2008;73:508–16.
[Medline](#) [Google Scholar](#)
284. Barr FD, Krohmer LJ, Hamilton JW, Sheldon LA. Disruption of histone modification and CARM1 recruitment by arsenic represses transcription at glucocorticoid receptor–regulated promoters. *PLoS One* 2009;4:e6766.
[CrossRef](#) [Medline](#) [Google Scholar](#)
285. Ashktorab H, Belgrave K, Hosseinkhah F, et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. *Digestive Dis Sci* 2009;54:2109–17.
[CrossRef](#) [Google Scholar](#)
286. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down–modulation. *Proc Natl Acad Sci USA* 2005;102:18081–86.
[Abstract/FREE Full Text](#)
287. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR–221 and miR–222 promotes cancer proliferation. *EMBO J* 2007;26:3699–708.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
288. Garofalo M, Di Leva G, Romano G, et al. miR–221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. *Cancer Cell* 2009;16:498–509.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
289. Mi SL, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. *Blood* 2007;110:75a.
[Google Scholar](#)
290. Saumet A, Vetter G, Bouttier M, et al. Transcriptional repression of microRNA genes by PML–RARA increases expression of key cancer proteins in acute promyelocytic leukemia. *Blood* 2009;113:412–21.
[Abstract/FREE Full Text](#)
291. Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA cluster miR–29a/b–1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta–secretase expression. *Proc Natl Acad Sci USA* 2008;105:6415–20.
[Abstract/FREE Full Text](#)
292. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR–17–92 cluster in anaplastic thyroid cancer cells. *Cancer Sci* 2008;99:1147–54.
[CrossRef](#) [Medline](#) [Google Scholar](#)
293. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 2004;101:11755–60.
[Abstract/FREE Full Text](#)
294. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR–145 in metastatic colorectal cancer. *BMC Cancer* 2009;9:374–90.
[CrossRef](#) [Medline](#) [Google Scholar](#)
295. Bandres E, Cubedo E, Agirre X, et al. Identification by Real–time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non–tumoral tissues.

Mol Cancer 2006;5:29–38.

[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

296. Malzkorn B, Wolter M, Grzendowski M, Stuhler K, Reifenberger G. Identification and functional characterization of microRNAs involved in the malignant progression of astrocytic gliomas. *Brain Pathol* 2010;20:539–50.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
297. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. *Mol Cancer* 2007;6:5–15.
[CrossRef](#) [Medline](#) [Google Scholar](#)
298. Budhu A, Jia HL, Forques M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. *Hepatology* 2008;47:897–907.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
299. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepatitis virus-associated hepatocellular carcinoma contributes to the malignant phenotype. *Am J Pathol* 2008;173:856–64.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
300. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Res* 2005;65:9628–32.
[Abstract/FREE Full Text](#)
301. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. *Leukemia* 2003;17:2533–35.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
302. Stirzaker C, Millar DS, Paul CL, et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. *Cancer Res* 1997;57:2229–37.
[Abstract/FREE Full Text](#)
303. Chen MN, Mao Q, Liu YH, Mao BY. Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2004;21:277–79.
[Medline](#) [Google Scholar](#)
304. Zhao YF, Shen SP, Jiang JY, Geng H, Guo JG, Xie LP. Methylation and expression of gene p16INK4a and RB in breast carcinoma. *Zhonghua Bing Li Xue Za Zhi* 2010;39:377–81.
[Medline](#) [Google Scholar](#)
305. Zhao Y, Tian X, Du J, et al. Methylation and expression of gene p16INK4a and RB in gastric carcinomas. *Beijing Da Xue Xue Bao* 2003;35:382–85.
[Medline](#) [Google Scholar](#)
306. Li H, Lu S, Fong L. Study on the status of methylation of Rb gene promoter in human esophageal cancer and effect of NMBzA on Rb gene promoter in monkey esophageal epithelium. *Zhonghua Zhong Liu Za Zhi* 1998;20:412–14.
[Medline](#) [Google Scholar](#)
307. Ke Q, Davidson T, Chen H, Kluz T, Costa M. Alterations of histone modifications and transgene silencing by nickel chloride. *Carcinogenesis* 2006;27:1481–88.
[Abstract/FREE Full Text](#)
308. Chen MW, Hua KT, Kao HJ, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. *Cancer Res* 2010;70:7830–40.
[Abstract/FREE Full Text](#)
309. Lefevre GM, Patel SR, Kim D, Tessarollo L, Dressler GR. Altering a histone H3K4 methylation pathway in glomerular podocytes promotes a chronic disease phenotype. *PLoS Genet* 2010;6:e1001142.
[CrossRef](#) [Medline](#) [Google Scholar](#)
310. Kumar R, Hunt CR, Gupta A, et al. Purkinje cell-specific males absent on the first (mMof) gene deletion results in an ataxia-telangiectasia-like neurological phenotype and backward walking in mice. *Proc Natl Acad Sci USA* 2011;108:3636–41.
[Abstract/FREE Full Text](#)
311. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin g1 is a target of miR-122a, a MicroRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Res* 2007;67:6092–99.
[Abstract/FREE Full Text](#)
312. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. *Proc Natl Acad Sci USA* 2008;105:7269–74.
[Abstract/FREE Full Text](#)
313. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-

- refractory prostate cancer. *Rna*—a Publication of the RNA Society 2008;14:417–24.
[Abstract/FREE Full Text](#)
314. Gonzalez–Ramirez I, Ramirez–Amador V, Irigoyen–Camacho ME, et al. hMLH1 promoter methylation is an early event in oral cancer. *Oral Oncol* 2011;47:22–26.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
315. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR, Hasan Q. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. *Cancer Biomark* 2010;7:1–10.
[Medline](#) [Web of Science](#) [Google Scholar](#)
316. Ling ZQ, Tanaka A, Li P, et al. Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. *Cancer Lett* 2010;297:244–51.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
317. Klein CB, Su L, Bowser D, Leszczynska J. Chromate–induced epimutations in mammalian cells. *Environ Health Perspect* 2002;110 Suppl 5:739–43.
[Medline](#) [Web of Science](#) [Google Scholar](#)
318. Lukiw WJ, Zhao YH, Cui JG. An NF–kappa B–sensitive micro RNA–146a–mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. *J Biol Chem* 2008;283:31315–22.
[Abstract/FREE Full Text](#)
319. Pogue AI, Li YY, Cui JG, et al. Characterization of an NF–kappa B–regulated, miRNA–146a–mediated down–regulation of complement factor H (CFH) in metal–sulfate–stressed human brain cells. *J Inorg Biochem* 2009;103:1591–95.
[CrossRef](#) [Medline](#) [Google Scholar](#)
320. Cheng YH, Ji RR, Yue JM, et al. MicroRNAs are aberrantly expressed in hypertrophic heart – Do they play a role in cardiac hypertrophy? *Am J Pathol* 2007;170:1831–40.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
321. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006;103:2257–61.
[Abstract/FREE Full Text](#)
322. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF–kappa B–dependent induction of microRNA miR–146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci USA* 2006;103:12481–86.
[Abstract/FREE Full Text](#)
323. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA–146 suppresses NF–kappa B activity with reduction of metastatic potential in breast cancer cells. *Oncogene* 2008;27:5643–5647.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
324. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR–146a gene and age of familial breast/ovarian cancer diagnosis. *Carcinogenesis* 2008;29:1963–66.
[Abstract/FREE Full Text](#)
325. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *New Engl J Med* 2005;353:1793–801.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
326. Xu T, Zhu Y, Wei QK, et al. A functional polymorphism in the miR–146a gene is associated with the risk for hepatocellular carcinoma. *Carcinogenesis* 2008;29:2126–31.
[Abstract/FREE Full Text](#)
327. Yanaihara N, Caplen N, Bowman E, et al. Unique MicroRNA molecular profiles in lung cancer diagnosis and prognosis. *Toxicol Pathol* 2006;34:1017–18.
[Google Scholar](#)
328. Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor–suppressive microRNAs silenced by DNA hypermethylation in oral cancer. *Cancer Res* 2008;68:2094–105.
[Abstract/FREE Full Text](#)
329. Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS–generating metal sulfates in primary human brain cells. *J Inorg Biochem* 2007;101:1265–69.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
330. Lukiw WJ. Micro–RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. *Neuroreport* 2007;18:297–300.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

331. Saba R, Goodman CD, Huzarewich RLCH, Robertson C, Booth SA. A miRNA Signature of Prion Induced Neurodegeneration. *PLoS One* 2008;3:e3652.
[CrossRef](#) [Medline](#) [Google Scholar](#)
332. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. *British J Haematol* 2008;142:732–44.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
333. Wang Y, Lee ATC, Ma JZI, et al. Profiling MicroRNA expression in hepatocellular carcinoma reveals MicroRNA-224 up-regulation and apoptosis inhibitor-5 as a MicroRNA-224-specific target. *J Biol Chem* 2008;283:13205–15.
[Abstract/FREE Full Text](#)
334. Tan HX, Wang QA, Chen LZ, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. *Med Oncol* 2010;27:654–60.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
335. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. *Int J Cancer* 2009;124:2236–42.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
336. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. *Am J Hum Genet* 2008;82:696–711.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
337. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. *PLoS One* 2008;3:e2698.
[CrossRef](#) [Medline](#) [Google Scholar](#)
338. Esteller M. Epigenetics in cancer. *N Engl J Med* 2008;358:1148–59.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
339. Heng JI, Nguyen L, Castro DS, et al. Neurogenin 2 controls cortical neuron migration through regulation of Rnd2. *Nature* 2008;455:114–18.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
340. Pereira MA, Tao L, Liu Y, Li L, Steele VE, Lubet RA. Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. *Int J Cancer* 2007;120:1150–53.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
341. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. *Cancer Res* 2005;65:6029–33.
[Abstract/FREE Full Text](#)
342. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res* 2005;65:7065–70.
[Abstract/FREE Full Text](#)
343. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *J Biol Chem* 2008;283:1026–33.
[Abstract/FREE Full Text](#)
344. Zhu SM, Si ML, Wu HL, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). *J Biol Chem* 2007;282:14328–36.
[Abstract/FREE Full Text](#)
345. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA* 2008;299:425–36.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
346. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. *JAMA* 2007;297:1901–08.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
347. Meng FY, Henson R, Wehbe-Janeck H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* 2007;133:647–58.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
348. Zhang K, Zhang R, Li X, Yin G, Niu X. Promoter methylation status of p15 and p21 genes in HPP-CFCs of bone marrow of patients with psoriasis. *Eur J Dermatol* 2009;19:141–46.
[Medline](#) [Google Scholar](#)
349. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. *Pathol Int* 2004;54:549–55.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
350. Lindberg D, Akerstrom G, Westin G. Evaluation of CDKN2C/p18, CDKN1B/p27

- and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. *Clin Endocrinol* 2008;68:271–77.
[Medline](#) [Google Scholar](#)
351. Kim M, Yim SH, Cho NS, et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. *Cancer Genet Cytogenet* 2009;195:59–65.
[CrossRef](#) [Medline](#) [Google Scholar](#)
352. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. *Leuk Res* 2005;29:653–59.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
353. Chen W, Wu Y, Zhu J, Liu J, Tan S, Xia C. Methylation of p16 and p15 genes in multiple myeloma. *Clin Med Sci J.* 2002;17:101–05.
[Google Scholar](#)
354. Gallardo F, Esteller M, Pujol RM, Costa C, Estrach T, Servitje O. Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. *Haematologica* 2004;89:1401–403.
[Abstract/FREE Full Text](#)
355. El-Shakankiry NH, Mossallam GI. p15 (INK4B) and E-cadherin CpG island methylation is frequent in Egyptian acute myeloid leukemia. *J Egypt Natl Canc Inst* 2006;18:227–32.
[Medline](#) [Google Scholar](#)
356. Matsuno N, Hoshino K, Nanri T, et al. p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. *Leuk Res* 2005;29:557–64.
[CrossRef](#) [Medline](#) [Google Scholar](#)
357. Wemmert S, Bettscheider M, Alt S, et al. p15 promoter methylation – a novel prognostic marker in glioblastoma patients. *Int J Oncol* 2009;34:1743–48.
[Medline](#) [Web of Science](#) [Google Scholar](#)
358. Yalcin A, Serin MS, Emekdas G, et al. Promoter methylation of P15(INK4B) gene is possibly associated with parvovirus B19 infection in adult acute leukemias. *Int J Lab Hematol* 2009;31:407–19.
[CrossRef](#) [Medline](#) [Google Scholar](#)
359. Berg T, Guo Y, Abdelkarim M, Fliegau M, Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. *Leuk Res* 2007;31:497–506.
[CrossRef](#) [Medline](#) [Google Scholar](#)
360. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. *Eur J Cancer* 2003;39:1881–87.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
361. Morgan DA, Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice. *J Hypertens* 2010;28:1913–19.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
362. Xiang Z, Proneth B, Dirain ML, Litherland SA, Haskell-Luevano C. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist. *Biochemistry* 2010;49:4583–600.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
363. Gucev ZS, Tasic V, Jancevska A, Kirovski I. A case of Silver–Russell syndrome (SRS): multiple pituitary hormone deficiency, lack of H19 hypomethylation and favourable growth hormone (GH) treatment response. *J Genet* 2009;88:239–43.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
364. Zeschnick M, Albrecht B, Buiting K, et al. IGF2/H19 hypomethylation in Silver–Russell syndrome and isolated hemihypoplasia. *Eur J Hum Genet* 2008;16:328–34.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
365. Chopra M, Amor DJ, Sutton L, Algar E, Mowat D. Russell–Silver syndrome due to paternal H19/IGF2 hypomethylation in a patient conceived using intracytoplasmic sperm injection. *Reprod Biomed Online* 2010;20:843–47.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
366. Dammann RH, Kirsch S, Schagdarsurengin U, et al. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. *Int J Oncol* 2010;36:171–79.
[Medline](#) [Google Scholar](#)
367. Baba Y, Noshio K, Shima K, et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Gastroenterology 2010;139:1855–64.

[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)

368. Li Y, Meng G, Huang L, Guo QN. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. *Hum Pathol* 2009;40:1441–47.
[CrossRef](#) [Medline](#) [Google Scholar](#)
369. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. *Cancer Res* 2002;62:6442–46.
[Abstract/FREE Full Text](#)
370. Ito Y, Koessler T, Ibrahim AE, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. *Hum Mol Genet* 2008;17:2633–43.
[Abstract/FREE Full Text](#)
371. Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer. *Biomark Insights* 2006;2:113–21.
[Medline](#) [Google Scholar](#)
372. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006;103:2257–61.
[Abstract/FREE Full Text](#)
373. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 2002;99:15524–29.
[Abstract/FREE Full Text](#)
374. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci USA* 2005;102:13944–49.
[Abstract/FREE Full Text](#)
375. Amb S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res* 2008;68:6162–70.
[Abstract/FREE Full Text](#)
376. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood* 2009;113:6669–80.
[Abstract/FREE Full Text](#)
377. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 MicroRNA family. *Cell* 2005;120:635–47.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
378. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev* 2007;21:1025–30.
[Abstract/FREE Full Text](#)
379. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 2006;9:189–98.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
380. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. *Cancer Res* 2007;67:9762–70.
[Abstract/FREE Full Text](#)
381. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor- α (ER α) and represses ER α messenger RNA and protein expression in breast cancer cell lines. *Mol Endocrinol* 2007;21:1132–47.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
382. Roccaro AM, Jia X, Ngo HT, et al. MicroRNA expression in the biology, prognosis, and therapy of waldenstrom macroglobulinemia. *Clin Lymphoma Myeloma* 2009;9:S126.
[Google Scholar](#)
383. Dixon-McIver A, East P, Mein CA, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. *PLoS One* 2008;3:e2141.
[CrossRef](#) [Medline](#) [Google Scholar](#)
384. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci USA* 2006;103:18255–60.
[Abstract/FREE Full Text](#)
385. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. *Circulation Res* 2007;100:416–24.
[Abstract/FREE Full Text](#)

Articles citing this article

Causal mediation analysis for longitudinal data with exogenous exposure

Biostatistics (2016) 17 (1): 122-134

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Epigenetic Regulation in Environmental Chemical Carcinogenesis and its Applicability in Human Health Risk Assessment

International Journal of Toxicology (2015) 34 (5): 384-392

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Causes of genome instability: the effect of low dose chemical exposures in modern society

Carcinogenesis (2015) 36 (Suppl_1): S61-S88

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Histone Hyperacetylation Up-regulates Protein Kinase C δ in Dopaminergic Neurons to Induce Cell Death: RELEVANCE TO EPIGENETIC MECHANISMS OF NEURODEGENERATION IN PARKINSON DISEASE

J Biol Chem (2014) 289 (50): 34743-34767

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Indices of methylation in sperm DNA from fertile men differ between distinct geographical regions

Hum Reprod (2014) 29 (9): 2065-2072

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Pandemie de multimorbidite idiopathique

cfp (2014) 60 (6): e290-e293

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Approach to patients with unexplained multimorbidity with sensitivities

cfp (2014) 60 (6): 533-538

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Pandemic of idiopathic multimorbidity

cfp (2014) 60 (6): 511-514

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Epigenetic Research in Cancer Epidemiology: Trends, Opportunities, and Challenges

Cancer Epidemiol. Biomarkers Prev. (2014) 23 (2): 223-233

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Republished: Environmental and occupational exposure to chemicals and telomere length in human studies

Postgrad. Med. J. (2013) 89 (1058): 722-728

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

A-clustering: a novel method for the detection of co-regulated methylation regions, and regions associated with exposure

Bioinformatics (2013) 29 (22): 2884-2891

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Environmental and occupational exposure to chemicals and telomere length in human studies

Occup. Environ. Med. (2013) 70 (10): 743-749

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation

Carcinogenesis (2013) 34 (9): 1955-1967

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter

Proc. Natl. Acad. Sci. USA (2013) 110 (11): 4315-4320

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Commentary: A step towards more comprehensive analyses of life course effects of mixtures of environmental factors

Int J Epidemiol (2012) 41 (3): 843-846

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Online ISSN 1464-3685 - Print ISSN 0300-5771

Copyright © 2016 International Epidemiological Association

Is epidemiology ready for epigenetics?

Int J Epidemiol (2012) 41 (1): 5-9

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

[Site Map](#) [Privacy Policy](#) [Cookie Policy](#) [Legal Notices](#) [Frequently Asked Questions](#)

Other Oxford University Press sites:

Oxford University Press

